Champions Oncology (CSBR) S-1 26 Apr 16 IPO registration Financial data

Document And Entity Information

Document And Entity Information	9 Months Ended
	Jan. 31, 2016
Document Information [Line Items]
Entity Registrant Name	CHAMPIONS ONCOLOGY, INC.
Entity Central Index Key	771,856
Entity Filer Category	Smaller Reporting Company
Document Type	S1
Amendment Flag	false
Document Period End Date	Jan. 31, 2016

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jan. 31, 2016	Apr. 30, 2015	Apr. 30, 2014
Current assets:
Cash and cash equivalents	$ 3,293	$ 9,357	$ 5,891
Accounts receivable, net	2,105	1,060	1,325
Prepaid expenses and other current assets	414	346	383
Total current assets	5,812	10,763	7,599
Restricted cash	150	163	165
Property and equipment, net	514	452	434
Goodwill	669	669	669
Total assets	7,145	12,047	8,867
Current liabilities:
Accounts payable	1,515	1,414	981
Accrued liabilities	257	373	587
Deferred revenue	2,875	2,009	2,091
Total current liabilities	4,647	3,796	3,659
Warrant liability		0	2,011
Other non-current liabilities	239	192	0
Total liabilities	$ 4,886	$ 3,988	5,670
Commitments and Contingencies
Stockholders’ equity:
Common stock, $.001 par value; 200,000,000 shares authorized; 8,963,590 shares issued and 8,702,237 shares outstanding as of January 31, 2016 and April 30, 2015, respectively	$ 9	$ 9	6
Treasury stock, at cost, 269,686 common shares as of January 31, 2016 and April 30, 2015	(1,252)	(1,252)	(1,252)
Additional paid-in capital	63,394	61,322	43,323
Accumulated deficit	(59,892)	(52,020)	(38,880)
Total stockholders’ equity	2,259	8,059	3,197
Total liabilities and stockholders’ equity	$ 7,145	$ 12,047	$ 8,867

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS [Parenthetical] - $ / shares	Jan. 31, 2016	Apr. 30, 2015	Apr. 30, 2014
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000	125,000,000
Common stock, shares issued	8,963,590	8,963,590	5,843,507
Common stock, shares outstanding	8,702,237	8,702,237	5,573,821
Treasury stock, common shares	269,686	269,686	269,686

UNAUDITED CONDENSED CONSOLIDATE

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015	Jan. 31, 2016	Jan. 31, 2015	Apr. 30, 2015	Apr. 30, 2014
Operating revenue:
Personalized oncology solutions	$ 416	$ 453	$ 1,387	$ 1,245	$ 1,663	$ 2,264
Translational oncology solutions	2,136	1,376	6,958	4,377	7,200	9,286
Total operating revenue	2,552	1,829	8,345	5,622	8,863	11,550
Costs and operating expenses:
Cost of personalized oncology solutions	479	674	1,661	2,190	2,733	2,731
Cost of translational oncology solutions	1,627	1,301	4,683	3,225	4,900	3,532
Research and development	999	1,093	3,018	3,757	4,845	2,265
Sales and marketing	779	1,094	2,688	3,340	4,283	3,155
General and administrative	1,041	1,086	4,062	3,944	5,340	6,127
Total costs and operating expenses	4,925	5,248	16,112	16,456	22,101	17,810
Loss from operations	(2,373)	(3,419)	(7,767)	(10,834)	(13,238)	(6,260)
Other (expense) income:
Change in fair value of warrant liability	0	621	0	1,401	981	(965)
Warrant modification charge					(586)	0
Other (expense)	(8)	(6)	(29)	(3)	(170)	(164)
Total other (expense) income	(8)	615	(29)	1,398	225	(1,129)
Loss before provision for income taxes	(2,381)	(2,804)	(7,796)	(9,436)	(13,013)	(7,389)
Provision for income taxes	31	12	76	27	127	17
Net loss	$ (2,412)	$ (2,816)	$ (7,872)	$ (9,463)	$ (13,140)	$ (7,406)
Net loss per common share outstanding
basic (in dollars per share)	$ (0.28)	$ (0.51)	$ (0.90)	$ (1.70)	$ (2.20)	$ (1.33)
diluted (in dollars per share)	$ (0.28)	$ (0.61)	$ (0.90)	$ (1.94)	$ (2.20)	$ (1.33)
Weighted average common shares outstanding
basic (in shares)	8,702,237	5,574,447	8,702,237	5,574,244	5,985,346	5,571,993
diluted (in shares)	8,702,237	5,603,798	8,702,237	5,603,595	6,424,410	5,571,993
Weighted average common shares outstanding basic and diluted (in shares)					5,985,346	5,571,993

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2015	Apr. 30, 2014
Net loss	$ (13,140)	$ (7,406)
Foreign currency translation adjustment	0	100
Comprehensive loss	$ (13,140)	$ (7,306)

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit	Accumulated Other Comprehensive Loss [Member]
Balance at Apr. 30, 2013	$ (9,206)	$ 3	$ (1,252)	$ 23,617	$ (31,474)	$ (100)
Balance (in shares) at Apr. 30, 2013		2,970,314	269,686
Stock-based compensation	2,807	$ 0	$ 0	2,807	0	0
Exercise of options and warrants	21	$ 0	$ 0	21	0	0
Exercise of options and warrants (in shares)		2,813	0
Issuance of restricted stock	0	$ 0	$ 0	0	0	0
Issuance of restricted stock (in shares)		6,250	0
Amendment to Redeemable Stock	16,881	$ 3	$ 0	16,879	0	0
Amendment to Redeemable Stock (in shares)		2,594,444	0
Foreign currency translation adjustment	100	$ 0	$ 0	0	0	100
Net loss	(7,406)	0	0	0	(7,406)	0
Balance at Apr. 30, 2014	3,197	$ 6	$ (1,252)	43,323	(38,880)	0
Balance (in shares) at Apr. 30, 2014		5,573,821	269,686
Stock-based compensation	2,948	$ 0	$ 0	2,948	0	0
Exercise of options and warrants	2	$ 0	$ 0	2	0	0
Exercise of options and warrants (in shares)		313	0
Conversion of convertible notes and accrued interest	2,060	$ 0	$ 0	2,060	0	0
Sale of common stock, net of issuance costs of $880k	11,161	$ 3	$ 0	11,158	0	0
Sale of common stock, net of issuance costs of $880k (in shares)		2,939,254	0
Issuance of share under anti-dilution provisions	1	$ 0	$ 0	1	0	0
Issuance of share under anti-dilution provisions (in shares)		188,704	0
Stock Option Modification	214	$ 0	$ 0	214	0	0
Reclassification of warrant Liability	1,616	0	0	1,616	0	0
Net loss	(13,140)	0	0	0	(13,140)	0
Balance at Apr. 30, 2015	8,059	$ 9	$ (1,252)	$ 61,322	$ (52,020)	$ 0
Balance (in shares) at Apr. 30, 2015		8,702,092	269,686
Net loss	(7,872)
Balance at Jan. 31, 2016	$ 2,259

CONSOLIDATED STATEMENT OF CHAN7

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) $ in Thousands	12 Months Ended
	Apr. 30, 2015USD ($)
Issuance Cost of Common Stock	$ 880

UNAUDITED CONDENSED CONSOLIDAT8

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015	Apr. 30, 2015	Apr. 30, 2014
Operating activities:
Net loss	$ (7,872)	$ (9,463)	$ (13,140)	$ (7,406)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	2,090	2,284	3,162	2,807
Net foreign currency remeasurement loss			0	124
Depreciation expense	114	166	214	213
Provision for bad debts	33	0
Change in fair value of warrant liability	0	(1,401)	(981)	965
Modification of warrant liability			586	0
Gain/loss on sales of assets			5	0
Changes in operating assets and liabilities:
Accounts receivable	(1,078)	233	265	(825)
Prepaid expenses and other current assets	(68)	125	37	(68)
Restricted cash	13	2	2	27
Accounts payable	101	381	433	(223)
Accrued liabilities	(116)	(167)	(232)	(24)
Other non-current liability	64	0	100	0
Deferred revenue	866	218	(82)	977
Net cash used in operating activities	(5,853)	(7,622)	(9,630)	(3,433)
Investing activities:
Purchase of property and equipment	(176)	(84)	(119)	(234)
Proceeds from sale of fixed assets			5	0
Net cash used in investing activities	(176)	(84)	(114)	(234)
Financing activities:
Private placement financing, net of financing costs of $880k			11,220	0
Proceeds from executive note financing	0	2,000	2,000	0
Payment of issuance costs related to March 2015 Private Placement	(18)	0
Capital lease payments	(17)	(5)	(12)	0
Proceeds from exercise of options	0	2	2	21
Net cash (used in)/provided by financing activities	(35)	1,997	13,210	21
Exchange rate effect on cash and cash equivalents			0	(24)
Decrease in cash and cash equivalents	(6,064)	(5,709)	3,466	(3,670)
Cash and cash equivalents, beginning of period	9,357	5,891	5,891	9,561
Cash and cash equivalents, end of period	3,293	182	9,357	5,891
Non-cash investing activities:
Purchase equipment under capital lease	$ 0	$ 124	124	0
Conversion of executive note financing			2,000	0
Reclassification of warrant liability to equity			$ 1,616	$ 0

UNAUDITED CONDENSED CONSOLIDAT9

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)	12 Months Ended
	Apr. 30, 2015USD ($)
Payments of Financing Costs	$ 880

Organization, Use of Estimates

Organization, Use of Estimates and Basis of Presentation	9 Months Ended	12 Months Ended
	Jan. 31, 2016	Apr. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Organization, Use of Estimates and Basis of Presentation Champions Oncology, Inc. (the “Company”), is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The Company’s TumorGraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology, in conjunction with related services, to offer solutions for two consumer groups: Personalized Oncology Solutions (“POS”) and Translational Oncology Solutions (“TOS”). POS assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The Company’s TOS business offers a technology platform to pharmaceutical and biotechnology companies using proprietary TumorGraft studies, which the Company believes may be predictive of how drugs may perform in clinical settings. The Company has three operating subsidiaries: Champions Oncology (Israel), Limited, Champions Biotechnology U.K., Limited and Champions Oncology Singapore, PTE LTD. Champions Oncology Singapore, PTE LTD is currently inactive and is in the process of being closed. For the three and nine months ended January 31, 2016 and 2015, there were no material revenues earned by these subsidiaries. The Company’s foreign subsidiaries functional currency is the U.S. dollar. Transaction gains and losses are recognized in earnings. The Company is subject to foreign exchange rate fluctuations in connection with the Company’s international operations. These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission or the SEC. All significant intercompany transactions and accounts have been eliminated. Certain information related to the Company’s organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States or GAAP has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in the Company’s annual consolidated financial statements for the year ended April 30, 2015, as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments necessary to fairly state our financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with the Company’s Annual Report on Form 10-K for the year ended April 30, 2015. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Liquidity Our liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products, working capital requirements, and other strategic initiatives. In the past, we have met these cash requirements through our sales of products and services, cash and cash equivalents, working capital management, and proceeds from certain private placements of our securities. As of January 31, 2016, we had positive working capital of $1.2 million and cash and cash equivalents on hand of $3.3 million. We believe that our cash and cash equivalents on hand at January 31, 2016 are adequate to fund our operations through at least April 2017. However, in order for us to continue as a going concern beyond this point, we may need to obtain capital from external sources. If we are unable to obtain additional financing, we may be required to reduce the scope of, or delay or eliminate, some of our research and development and other activities, which could harm our financial condition and operating results. Financing may not be available on acceptable terms or at all, and our failure to raise capital when needed could negatively impact our growth plans and our financial condition and results of operations. Additional equity financing may be dilutive to the holders of our common stock and debt financing, if available, may involve significant cash payment obligations and covenants and/or financial ratios that could restrict our ability to operate our business. Reverse Stock Split On October 15, 2013, the shareholders of the Company authorized our Board of Directors to effect a reverse stock split of all outstanding shares of common stock, warrants and options. The Board of Directors subsequently approved the implementation of a reverse stock split at a ratio of one-for-twelve shares, which became effective on August 12, 2015. All share and per share data in these condensed consolidated financial statements and related notes hereto have been retroactively adjusted to account for the effect of the reverse stock split. Earnings Per Share Basic net loss per share is computed by dividing the net loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss for the period by the weighted-average number of shares of common stock plus dilutive potential common stock considered outstanding during the period. Such dilutive shares consist of incremental shares that would be issued upon exercise of the Company’s common stock purchase warrants and stock options. For the three and nine months ended January 31, 2016, basic and dilutive loss per share were the same, as the potentially dilutive securities did not have a dilutive effect. Although there were net losses for the three and nine months ended January 31, 2015, the gain from the change in fair value of the warrant liability for these periods had a dilutive effect on earnings per share. Three Months Ended Nine Months Ended 2016 2015 2016 2015 Basic loss per share computation Net loss attributable to common stockholders $ (2,412,381 ) $ (2,816,465 ) $ (7,872,115 ) $ (9,462,281 ) Weighted Average common shares – basic 8,702,237 5,574,447 8,702,237 5,574,244 Basic net loss per share $ (0.28 ) $ (0.51 ) $ (0.90 ) $ (1.70 ) Diluted loss per share computation Net loss attributable to common stockholders $ (2,412,381 ) $ (2,816,465 ) $ (7,872,115 ) $ (9,462,281 ) Less: Gain on derivative warrant liability — 620,687 — 1,401,314 Loss available to common stockholders $ (2,412,381 ) $ (3,437,152 ) $ (7,872,115 ) $ (10,863,595 ) Weighted Average common shares 8,702,237 5,574,447 8,702,237 5,574,244 Incremental shares from assumed exercise of warrants and stock options — 29,351 — 29,351 Adjusted weighted average share – diluted 8,702,237 5,603,798 8,702,237 5,603,595 Diluted net loss per share $ (0.28 ) $ (0.61 ) $ (0.90 ) $ (1.94 ) January 31, 2016 2015 Stock options 2,212,571 1,999,167 Warrants 2,109,840 260,556 Total common stock equivalents 4,322,411 2,259,723 Income Taxes Deferred income taxes have been provided to show the effect of temporary differences between the recognition of expenses for financial and income tax reporting purposes and between the tax basis of assets and liabilities, and their reported amounts in the consolidated financial statements. In assessing the realizability of deferred tax assets, the Company assesses the likelihood that deferred tax assets will be recovered through tax planning strategies or from future taxable income, and to the extent that recovery is not likely or there is insufficient operating history, a valuation allowance is established. The Company adjusts the valuation allowance in the period management determines it is more likely than not that net deferred tax assets will or will not be realized. Changes in valuation allowances from period to period are included in the tax provision in the period of change. As of January 31, 2016 and 2015, the Company provided a valuation allowance for all net deferred tax assets, as recovery is not more likely than not based on an insufficient history of earnings. Tax positions are positions taken in a previously filed tax return or positions expected to be taken in a future tax return that are reflected in measuring current or deferred income tax assets and liabilities reported in the consolidated financial statements. Tax positions include, but are not limited to, the following: • An allocation or shift of income between taxing jurisdictions; • The characterization of income or a decision to exclude reportable taxable income in a tax return; or • A decision to classify a transaction, entity or other position in a tax return as tax exempt. The Company reflects tax benefits only if it is more likely than not that we will be able to sustain the tax position, based on its technical merits. If a tax benefit meets this criterion, it is measured and recognized based on the largest amount of benefit that is cumulatively greater than 50% likely to be realized. The Company has approximately $165,000 and $100,000 of unrecognized tax liabilities as of January 31, 2016 and April 30, 2015, respectively. The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on the Company’s balance sheets at January 31, 2016 and April 30, 2015, and has not recognized interest and/or penalties in the statement of operations for either period. We do not anticipate any significant unrecognized tax benefits will be recorded during the next 12 months. The income tax provision for the nine months ended January 31, 2016 and 2015 was $76,000 and $27,000, respectively.	The share and per share information in these Consolidated Financial Statements as of and for the years ended April 30, 2015 and 2014 gives effect to a 1-for-12 reverse stock split of our outstanding shares of common stock that became effective on August 12, 2015 Background Champions Oncology, Inc. (the “Company”), is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The Company’s TumorGraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology, in conjunction with related services, to offer solutions for two consumer groups: Personalized Oncology Solutions (“POS”) and Translational Oncology Solutions (“TOS”). POS assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The Company’s TOS business offers a technology platform to pharmaceutical and biotechnology companies using proprietary TumorGraft studies, which the Company believes may be predictive of how drugs may perform in clinical settings. The Company has three operating subsidiaries: Champions Oncology (Israel), Limited, Champions Biotechnology U.K., Limited and Champions Oncology Singapore, PTE LTD. For the years ended April 30, 2015 and 2014, there were no material revenues earned by these subsidiaries. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Apr. 30, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 2. Summary of Significant Accounting Policies The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation. The Company’s foreign subsidiaries functional currency is the U.S. dollar. Transaction gains and losses are recognized in earnings. The Company is subject to foreign exchange rate fluctuations in connection with the Company’s international operations. The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company considers all highly liquid investments purchased with a maturity of three months or less at the time of purchase, to be cash equivalents. At various times, the Company has amounts on deposit at financial institutions in excess of federally insured limits. The carrying value of cash and cash equivalents, accounts receivable, prepaid expenses, deposits and other receivables, accounts payable, and accrued liabilities approximate their fair value based on the liquidity or the short-term maturities of these instruments. The fair value hierarchy promulgated by GAAP consists of three levels: · Level one · Level two · Level three Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company had one liability measured at fair value on a recurring basis, which relate to warrants that were issued in connection with the 2011 and 2013 private placements of the Company’s securities. On March 11, 2015 the Company entered into a securities purchase agreement and amended certain agreements which eliminated the provisions within the warrant agreements requiring the liability classification of the warrant liability. Accordingly, the warrant liability was reclassified to equity at the date of such modification which is discussed more fully in Note 7. As of March 11, 2015 and April 30, 2014, these warrants had an estimated fair value of $ 1.6 2 2015 2014 Balance beginning of year $ (2,011) $ (1,046) Transfers to (from) Level 3 — — Change in fair value included in earnings 981 (965) Modification Charge (586) Reclassification to equity 1,616 — Balance end of year $ — $ (2,011) Accounts receivable represent amounts due under agreements with pharmaceutical and biotechnology companies for TOS and amounts due under agreements with patients for POS. At each reporting period, the Company evaluates open accounts receivable for collectability and records an allowance for potentially uncollectible accounts. For both April 30, 2015 and 2014, the allowance for these accounts was $ 2,000 636,000 884,000 As of April 30, 2015 and 2014, the Company has restricted cash of $ 163,000 165,000 Property and equipment is recorded at cost and primarily consists of laboratory equipment, furniture and fixtures, and computer hardware and software. Depreciation and amortization is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from three to seven years. April 30, 2015 2014 Furniture and fixtures $ 70 $ 69 Computer equipment and software 685 655 Laboratory equipment 493 296 Leasehold improvements 2 2 Total property and equipment 1,250 1,022 Less: Accumulated depreciation and amortization (798) (588) Property and equipment, net $ 452 $ 434 Depreciation and amortization expense was $ 214,000 213,000 124,000 12,405 In November 2014, the Company entered into a lease for laboratory equipment. The lease is a capital lease that has costs of approximately $ 149,000 3,000 For the Years Ended April 30, 2016 23 2017 24 2018 25 2019 26 2020 16 Total minimum lease payments $ 114 Less: current maturity (23) Long-term maturity 91 The present value of minimum future obligations shown above is calculated based on interest rate of 5 Impairment of Long-Lived Assets Impairment losses are to be recognized when the carrying amount of a long-lived asset is not recoverable or exceeds its fair value. The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that a carrying value may not be recoverable. The Company uses estimates of future cash flows over the remaining useful life of a long-lived asset or asset group to determine the recoverability of the asset. These estimates only include the net cash flows directly associated with, and that are expected to arise as a direct result of, the use and eventual disposition of the asset or asset group. The Company has not recognized any impairment losses for the Company’s long-lived assets for the years ending April 30, 2015 and 2014. Goodwill represents the excess of the cost over the fair market value of the net assets acquired including identifiable assets. Goodwill is tested annually, or more frequently if circumstances indicate potential impairment, by comparing its fair value to its carrying amount. The determination of whether or not goodwill is impaired involves significant judgment. Although the Company believes its goodwill is not impaired, changes in strategy or market conditions could significantly impact the judgments and may require future adjustments to the carrying value of goodwill. The Company uses a two-step process to test for goodwill impairment. The first step is to screen for potential impairment, while the second step measures the amount of the impairment, if any. The first step of the goodwill impairment test compares the fair value of each reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired. If the carrying value of the reporting unit’s net assets, including goodwill, exceeds the fair value of the reporting unit, then the Company determines the implied fair value of goodwill. If the carrying value of goodwill exceeds its implied fair value, then an impairment of goodwill has occurred and an impairment loss would be recognized for the difference between the carrying amount and the implied fair value of goodwill as a component of operating income. The implied fair value of goodwill is calculated by subtracting the fair value of tangible and intangible assets associated with the reporting unit from the fair value of the unit. The Company tests for goodwill impairment at the operating segment level. The Company has not recognized any impairment losses for the Company’s goodwill for the years ending April 30, 2015 and 2014. Deferred revenue represents payments received in advance for products to be delivered. When products are delivered, deferred revenue is then recognized as earned. Warrant liability represented the fair value of warrants issued in connection with the 2011 and 2013 private placements of the Company’s common stock, which are described more fully in Note 8. These warrants were presented as liabilities based on the certain exercise price reset provisions. The liability, which was recorded at fair value on the accompanying consolidated balance sheets, was calculated by the Monte Carlo simulation valuation method. The change in fair value of these warrants were recognized as other income or expense in the consolidated statements of operations. On March 11, 2015 the Company entered into a securities purchase agreement and amended the 2011 and 2013 warrant agreements which eliminated the liability feature of these warrants. Such warrants were transferred to equity which is discussed more fully in Note 7. The Company derives revenue from its POS and TOS businesses. Personalized oncology solutions assist physicians by providing information to help guide the development of personalized treatment plans for their patients using our core offerings, including testing oncology drugs and drug combinations on personalized TumorGrafts, and through other products. Translational oncology solutions offer a preclinical TumorGraft platform to pharmaceutical and biotechnology companies using proprietary TumorGraft studies, which the Company believes may be predictive of how drugs may perform in clinical settings. The Company recognizes revenue when the following four basic criteria are met: (i) a contract has been entered into with its customers; (ii) delivery has occurred or services rendered to its customers; (iii) the fee is fixed and determinable as noted in the contract; and (iv) collectability is reasonably assured. The Company utilizes a proportional performance revenue recognition model for its TOS business, under which it recognizes revenue as performance occurs, based on the relative outputs of the performance that have occurred up to that point in time under the respective agreement, typically the delivery of reports to its customers documenting the results of testing protocols. When a POS or TOS arrangement involves multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent separate units of accounting. The Company performs this evaluation at the inception of an arrangement and as each item in the arrangement is delivered. Generally, the Company accounts for a deliverable (or a group of deliverables) separately if: (i) the delivered item(s) has standalone value to the customer, and (ii) if the Company has given the customer a general right of return relative to the delivered item(s) and the delivery or performance of the undelivered item(s) or service(s) is probable and substantially in the Company’s control. All revenue from contracts determined not to have separate units of accounting is recognized based on consideration of the most substantive delivery factor of all the elements in the contract or if there is no predominant deliverable upon delivery of the final element of the arrangement. During the third quarter of fiscal year 2014 we entered into a contract that may require the replacement of licensed tumors in the event that certain contractual terms have not been satisfied. Due to such requirements we have estimated an amount of licensed tumors that may need to be replaced, and we have deferred this revenue until all provisions of the agreement have been met. There was $ 258,000 Cost of POS consists of costs related to POS revenue earned from implantations, drug panels, tumor boards, and gene sequencing services, as well as indirect internal costs, such as salaries for personnel directly engaged in these products. Direct costs associated with implantation revenues are primarily related to mice purchases and maintenance and shipping of tumor tissue. Direct drug panel costs are primarily incurred from mice purchases and maintenance and drug purchases. Direct tumor board costs are primarily related to physicians’ honorariums and any tumor board participation costs such as travel, lodging and meals. Direct gene sequencing costs are primarily related to costs billed from the gene sequencing service provider. All costs are expensed as incurred. Cost of TOS consists of costs related to TOS revenue. Direct costs include mice purchases and maintenance costs for studies completed internally and charges from CROs for studies handled externally. Indirect costs include salaries for personnel directly engaged in providing TOS products. All costs of performing studies in-house are expensed as incurred. All costs of performing studies from external sources, if any, are expensed when received. Research and development costs represent both costs incurred internally for research and development activities, including personnel costs and mice purchases and maintenance, as well as costs incurred externally to facilitate research activities, such as tumor tissue procurement and characterization expenses. All research and development costs are expensed as incurred. Sales and Marketing Selling and marketing expenses represent costs incurred to promote the Company’s products offered, including salaries, benefits and related costs of our sales and marketing personnel, and represent costs of advertising and other selling and marketing expenses. All sales and marketing costs, including advertising costs, are expensed as incurred. Basic net loss per share is computed by dividing the net loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss for the period by the weighted-average number of shares of common stock plus dilutive potential common stock considered outstanding during the period. Such dilutive shares consist of incremental shares that would be issued upon exercise of the Company’s derivative warrants, which were reclassified to equity as discussed in note 7. Year Ended April 30, 2015 2014 Basic loss per share computation Net loss attributable to common stockholders $ (13,139,820) $ (7,406,367) Weighted Average common shares – basic 5,985,346 5,571,993 Basic net loss per share $ (2.20) $ (1.33) Diluted loss per share computation Net loss attributable to common stockholders $ (13,139,820) $ (7,406,367) Less: Gain on derivative warrant liability 980,519 — Loss available to common stockholders $ (14,120,339) $ (7,406,367) Weighted Average common shares 5,985,346 5,571,993 Incremental shares from assumed exercise of warrants and stock options 439,065 — Adjusted weighted average share – diluted 6,424,410 5,571,993 Diluted net loss per share $ (2.20) $ (1.33) Year Ended April 30, 2015 2014 Stock options 2,004,002 1,945,920 Warrants 2,109,840 273,056 Total common stock equivalents 4,113,842 2,218,975 The Company typically recognizes expense for share-based payments based on the fair value of awards on the date of grant. The Company uses the Black-Scholes option pricing model to estimate fair value. The Black-Scholes option valuation model was developed for use in estimating the fair value of short-traded options that have no vesting restrictions and are fully transferable. The option pricing model requires the Company to estimate certain key assumptions such as expected life, volatility, risk free interest rates and dividend yield to determine the fair value of share-based awards. These assumptions are based on historical information and management judgment. The risk-free interest rate used is based on the United States treasury security rate with a term consistent with the expected term of the award at the time of the grant. Since the Company has limited option exercise history, it has generally elected to estimate the expected life of an award based upon the Securities and Exchange Commission-approved “simplified method” noted under the provisions of Staff Accounting Bulletin No. 107 with the continued use of this method extended under the provisions of Staff Accounting Bulletin No. 110. The Company expenses share-based payments over the period that the awards are expected to vest, net of estimated forfeitures. If actual forfeitures differ from management’s estimates, compensation expense is adjusted. The Company expenses modification charges in the period of modification and, if required, over the remaining period the awards are expected to vest. The Company will report cash flows resulting from tax deductions in excess of the compensation cost recognized from those options (excess tax benefits) as financing cash flows, if they should arise. Deferred income taxes have been provided to show the effect of temporary differences between the recognition of expenses for financial and income tax reporting purposes and between the tax basis of assets and liabilities, and their reported amounts in the consolidated financial statements. In assessing the realizability of deferred tax assets, the Company assesses the likelihood that deferred tax assets will be recovered through tax planning strategies or from future taxable income, and to the extent that recovery is not likely or there is insufficient operating history, a valuation allowance is established. The Company adjusts the valuation allowance in the period management determines it is more likely than not that net deferred tax assets will or will not be realized. Changes in valuation allowances from period to period are included in the tax provision in the period of change. As of April 30, 2015 and 2014, the Company provided a valuation allowance for all net deferred tax assets, as recovery is not more likely than not based on an insufficient history of earnings. Tax positions are positions taken in a previously filed tax return or positions expected to be taken in a future tax return that are reflected in measuring current or deferred income tax assets and liabilities reported in the consolidated financial statements. Tax positions include, but are not limited to, the following: · An allocation or shift of income between taxing jurisdictions; · The characterization of income or a decision to exclude reportable taxable income in a tax return; or · A decision to classify a transaction, entity or other position in a tax return as tax exempt. The Company reflects tax benefits only if it is more likely than not that we will be able to sustain the tax position, based on its technical merits. If a tax benefit meets this criterion, it is measured and recognized based on the largest amount of benefit that is cumulatively greater than 50% likely to be realized. The Company has $ 100 The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on the Company’s balance sheets at April 30, 2015 and 2014, and has not recognized interest and/or penalties in the statement of operations for either period. We do not anticipate any significant unrecognized tax benefits will be recorded during the next 12 months. In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers” In June 2014, FASB has issued Accounting Standards Update (“ASU”) No. 2014-12, “Compensation — Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period”. In August 2014, FASB issued Accounting Standards Update (“ASU”) 2014-15, “Presentation of Financial Statements — Going Concern: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”

Significant Customers

Significant Customers	12 Months Ended
	Apr. 30, 2015
Significant Customer [Abstract]
Significant Customer [Text Block]	Note 4. Significant Customers For the year ended April 30, 2015, three of our customers accounted for more than 10.0 0.9 0.9 0.8 For the year ended April 30, 2014, three of our customers accounted for more than 10.0 1.6 1.5 1.5 For the year ended April 30, 2015, two of our customers accounted for more than 10.0 153,446 119,540 14.5 11.3 For the year ended April 30, 2014, two of our customers accounted for more than 10.0 398,053 171,962 30.4 13.2

Property and Equipment

Property and Equipment	9 Months Ended
	Jan. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 2. Property and Equipment Property and equipment is recorded at cost and consists of laboratory equipment, leasehold improvements, furniture and fixtures, and computer equipment and software. Depreciation is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from three to seven years. January 31, April 30, 2016 2015 (unaudited) Furniture and fixtures $ 73 $ 70 Computer equipment and software 710 685 Laboratory equipment 641 493 Leasehold improvements 2 2 Total property and equipment 1,426 1,250 Less: Accumulated depreciation (912) (798) Property and equipment, net $ 514 $ 452 Depreciation expense, excluding expense recorded under capital lease, was $ 31,000 52,000 95,000 166,000 124,000 6,000 6,000 19,000 12,000 Capital Lease In November 2014, the Company entered into a lease for laboratory equipment. The lease is a capital lease that has costs of approximately $ 149,000 For the Years Ended April 30, Total 2016 (remaining) $ 6 2017 24 2018 25 2019 27 2020 16 Total minimum payments 98 Less: amount representing interest (10) Present value of minimum payments 88 Less: current portion (24) $ 64 The present value of minimum future obligations shown above is calculated based on an interest rate of 5

Share-Based Payments

Share-Based Payments	9 Months Ended	12 Months Ended
	Jan. 31, 2016	Apr. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	The Company has in place a 2010 Equity Incentive Plan and a 2008 Equity Incentive Plan. In general, these plans provide for stock-based compensation in the form of (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights to the Company’s employees, directors and non-employees. The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards. Stock-based compensation in the amount of $567,000 and $657,000 was recognized for the three months ended January 31, 2016 and 2015, respectively, and $2,090,000 and $2,284,000 for the nine months ended January 31, 2016 and 2015, respectively. Three Months Ended Nine Months Ended 2016 2015 2016 2015 General and administrative $ 488 $ 474 $ 1,600 $ 1,530 Sales and marketing 27 114 173 447 Research and development 49 65 262 267 TOS cost of sales 2 2 28 20 POS cost of sales 1 2 27 20 Total stock-based compensation expense $ 567 $ 657 $ 2,090 $ 2,284 Stock Option Grants Three Months Ended Nine Months Ended 2016 2015 2016 2015 Expected term in years 2.5 – 6 — 2.5 – 6 3 – 6 Risk-free interest rates 0.995% – 1.75% — 0.995% – 1.77% 0.79% – 1.94% Volatility 82.72% – 91.98% — 82.72% – 92.32% 85.8% – 102.1% Dividend yield 0% — 0% 0% The weighted average fair value of stock options granted during the three months ended January 31, 2016 and 2015 was $3.12 and nil, respectively. The weighted average fair value of stock options granted during the nine months ended January 31, 2016 and 2015 was $3.60 and $8.04, respectively. Non- Directors Total Weighted Weighted Aggregate Outstanding, May 1, 2015 57,917 1,946,085 2,004,002 $ 5.74 6.7 $ 4,166,000 Granted — 331,582 331,582 5.33 8.9 — Exercised — — — — Forfeited — (38,140 ) (38,140 ) 6.64 Expired (6,667 ) (78,206 ) (84,873 ) 6.91 Outstanding, January 31, 2016 51,250 2,161,321 2,212,571 5.61 6.4 $ 1,000 Vested and expected to vest as of January 31, 2016 51,250 2,161,321 2,212,571 5.61 6.4 $ 1,000 Exercisable as of January 31, 2016 34,271 1,644,223 1,678,494 5.76 5.8 $ 1,000 Included in the balances outstanding in the table above are 224,663 options (which vest based on service criteria) granted to each of the Company’s Chief Executive Officer and its President as of November 5, 2013 as part of their employment agreements. In addition to the above, there are 224,663 additional options granted to each of the Company’s Chief Executive Officer and President which vest based on both service and performance criteria. The service-based conditions of these options provide for vesting to occur monthly over a period of three years. The service-based options are expensed on a straight-line basis. Since the straight-line method is not available for performance or market-based share-based payments, the 224,663 performance-based options will be expensed on an accelerated basis once the Company determines it is probable that the performance-based conditions will be met. Stock Purchase Warrants As of January 31, 2016 and April 30, 2015, the Company had warrants outstanding for the purchase of 2,109,840 shares of its common stock, all of which were exercisable. Of these warrants, 1,849,285 were issued in connection with the March 2015 Private Placement as further discussed in Note 7 in the Company’s Form 10-K for the fiscal year ended April 30, 2015. Number of Weighted Weighted Aggregate Outstanding, May 1, 2015 2,109,840 $ 5.54 4.6 $ 3,764,871 Granted — — — — Exercised — — — — Expired — — — — Outstanding, January 31, 2016 2,109,840 $ 5.54 3.9 $ —	Stock-based compensation in the amount of $3.2 million and $2.8 million was recognized for years ended April 30, 2015 and 2014, respectively. Included in 2015 stock-based compensation expense under “general and administrative” line item is the option modification charge of $213,952. Year Ended April 30, 2015 2014 General and administrative $ 2,204 $ 2,298 Sales and marketing 561 352 Research and development 352 36 TOS cost of sales 23 56 POS cost of sales 22 65 Total stock-based compensation expense $ 3,162 $ 2,807 2010 Equity Incentive Plan On February 18, 2011, shareholders owning a majority of the issued and outstanding shares of the Company executed a written consent approving the 2010 Equity Incentive Plan (“2010 Equity Plan”). The purpose of the 2010 Equity Plan is to grant (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights (collectively, stock-based compensation) to its employees, directors and non-employees. Total stock awards under the 2010 Equity Plan shall not exceed 30,000,000 shares of common stock. Options and Stock Appreciation Rights expire no later than ten years from the date of grant and the awards vest as determined by the Board of Directors. Options and Stock Appreciation Rights have a strike price not less than 100% of the fair market value of the common stock subject to the option or right at the date of grant. 2008 Equity Incentive Plan The Company has previously granted (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights (collectively, stock-based compensation) to its employees, directors and non-employees under a 2008 Equity Incentive Plan (the “2008 Equity Plan”). Such awards may be granted by the Company’s Board of Directors. Options granted under the 2008 Equity Plan expire no later than ten years from the date of grant and the awards vest as determined by the Board of Directors. For share-based payments to non-employee consultants under both the 2010 and 2008 Equity Incentive Plan, the fair value of the share-based consideration issued is used to measure the transaction, as management believes this to be a more reliable measure of fair value than the services received. The fair value of the award is expensed over the period service is provided to the Company; however, it is ultimately measured at the price of the Company’s common stock or the fair value of stock options using the Black-Scholes valuation model on the date that the commitment for performance by the non-employee consultant has been reached or performance is complete, which is generally the vesting date of the award. Director Compensation Plan On December 12, 2013, the Compensation Committee of the Board of Directors of the Company adopted changes to the Director Compensation Plan of 2010 (the “Director Plan”) effective commencing December 1, 2013. Under the Director Plan, independent directors of the Company are entitled to an annual award of a five-year option to purchase 8,333 shares of the Company’s common stock, and the Chairman of the Board of the Company is entitled to an annual award of a five year option to purchase 16,667 shares of the Company’s common stock. Independent directors who serve as chairperson of a committee will also receive an annual grant of a five-year option to purchase 1,667 shares of the Company’s unregistered common stock. All options issued under the Director Plan vest quarterly at a rate of 25%. Option grants will typically be issued after the annual shareholder meeting which will generally be held in October of each year. New directors will receive a grant upon joining the Board equal to the pro-rata annual grant for the remainder of the year. Options issued under the Director Plan are issued pursuant to the 2010 Equity Plan. Stock Option Grants Year Ended April 30, 2015 2014 Expected term in years 2.5 – 6.0 3.0 – 6.0 Risk-free interest rates 0.8% – 1.9% 0.7% – 2.4% Volatility 86% – 102% 84% – 102% Dividend yield 0% 0% Non- Employees Directors Total Weighted Weighted Aggregate Outstanding, May 1, 2014 63,750 1,882,170 1,945,920 $ 12.12 7.5 $ 985,000 Granted 6,667 1,756,714 1,763,380 7.92 Exercised — (313 ) (313 ) 5.88 Canceled — (1,656,073 ) (1,656,073 ) 12.48 Forfeited — (12,604 ) (12,604 ) 11.52 Expired (12,500 ) (23,809 ) (36,309 ) 11.88 Outstanding, April 30, 2015 57,917 1,946,085 2,004,002 5.74 6.7 $ 4,166,000 Vested and expected to vest as of April 30, 2015 57,917 1,946,085 2,004,002 6.7 $ 4,166,000 Vested as of April 30, 2015 40,625 1,385,298 1,425,923 5.88 5.9 $ 2,879,000 Non- Directors Total Weighted Weighted Aggregate Outstanding, May 1, 2013 63,750 1,093,767 1,157,517 $ 10.20 7.0 $ 89,000 Granted — 816,111 816,111 14.76 Exercised — (2,813 ) (2,813 ) 7.56 Canceled — — — — Forfeited — (6,042 ) (6,042 ) 9.84 Expired — (18,854 ) (18,854 ) 8.76 Outstanding, April 30, 2014 63,750 1,882,170 1,945,920 12.12 7.5 $ 985,000 Vested and expected to vest as of April 30, 2014 63,750 1,882,170 1,945,920 7.5 $ 985,000 Vested as of April 30, 2014 43,524 1,086,857 1,130,381 10.20 6.1 $ 927,000 Included in the balances outstanding in the table above are 224,663 options (which vest based on service criteria) granted to the Company’s Chief Executive Officer and its President as of November 5, 2013 as part of their new employment agreements. In addition to the above, there are 224,663 additional options granted to the Company’s Chief Executive Officer and President which vest based on both service and performance criteria. The service-based conditions of these options provide for vesting to occur monthly over a period of three years. The service-based options, like all of the Company’s service-based options, are expensed on a straight-line basis. Since the straight-line method is not available for performance or market-based share-based payments, the 224,663 performance-based options will be expensed on an accelerated basis once the Company determines it is probable that the performance-based conditions will be met. On March 16, 2015, the Company and certain members of its senior management team agreed to exchange existing options to purchase shares of the Company’s common stock with new options. The new options have a lower exercise price for fewer shares and have the same vesting schedules and the same termination expiration dates as the existing options. The Company used the Black Scholes valuation method to determine if the modification created additional stock option expense. Due to the modification the Company had an additional stock option modification expense for the current period of $213,951 and future additional stock option modification expense of $386,578. All additional expense will be recorded as stock option expense. The members of the senior management team whose options were exchanged include Joel Ackerman, the Company’s Chief Executive Officer and a member of its Board of Directors, Ronnie Morris, the Company’s President and a member of its Board of Directors, James McGorry, the Company’s Executive Vice President and General Manager, Translational Oncology Solutions and David Miller, the Company’s Vice President, Finance. As a result of the option exchange, an aggregate of 1,656,073 existing options with exercise prices ranging from $5.64 to $15.96 per share were exchanged for an aggregate of 1,468,161 new options with exercise prices of $4.92 per share. Also on March 16, 2015, the Company and each of Mr. Ackerman and Dr. Morris agreed to amend their employment agreements with the Company. Their current employment agreements provide that, for the year from November 1, 2014 to October 31, 2015, Mr. Ackerman and Dr. Morris’s salaries would be paid half in cash and half in options to purchase shares of common stock. To conserve the Company’s cash, Mr. Ackerman and Dr. Morris have agreed to accept all of their compensation in options, and none of it in cash for such year. Mr. Ackerman received 96,283 options and Dr. Morris received 90,358 options. These options were granted on March 16, 2015 and vest over a one year period starting from November 1, 2014 which is concurrent with their employment contract. Restricted Stock Grants The total fair value of shares vested during the years ended April 30, 2015 and 2014 was nil and $15,000, respectively. As of April 30, 2015, there was no unrecognized stock compensation expense related to nonvested restricted stock awards. Stock Purchase Warrants As of April 30, 2015, the Company had warrants outstanding for the purchase of 2,109,840 shares of its common stock, all of which were exercisable. Of these warrants, 1,849,285 were issued in connection with the March 2015 Private Placement as further discussed in Note 7. Number of Weighted Weighted Aggregate Outstanding, May 1, 2014 273,056 $ 7.32 2.9 $ 984,333 Granted 1,849,285 5.64 4.9 3,108,271 Exercised — — — — Forfeited — — — — Expired (12,500 ) — — — Outstanding, April 30, 2015 2,109,840 $ 5.82 4.6 $ 3,247,604 Number of Weighted Weighted Aggregate Outstanding, May 1, 2013 273,056 $ 7.32 3.9 $ — Granted — — — — Exercised — — — — Forfeited — — — — Expired — — — — Outstanding, April 30, 2014 273,056 $ 7.32 2.9 $ 984,333

Related Party Transactions

Related Party Transactions	9 Months Ended	12 Months Ended
	Jan. 31, 2016	Apr. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 4. Related Party Transactions Related party transactions include transactions between the Company and its shareholders, management, or affiliates. The following transactions, which are pre-approved by the Board of Directors, were in the normal course of operations and were measured and recorded at the exchange amount, which is the amount of consideration established and agreed to by the parties. Consulting Services During the nine months ended January 31, 2016 and 2015, the Company paid a member of its Board of Directors $54,000 and $75,000, respectively, for consulting services unrelated to his duties as a board member. During the nine months ended January 31, 2016 and 2015, the Company paid a board member’s company $8,800 and nil, respectively, for consulting services unrelated to his duties as a board member. All of the amounts paid to these related parties have been recognized and expensed in the period the services were performed.	Note 9. Related Party Transactions Related party transactions include transactions between the Company and its shareholders, management, or affiliates. The following transactions were in the normal course of operations and were measured at the exchange amount, which is the amount of consideration established and agreed to by the parties. Consulting Services During the years ended April 30, 2015 and 2014, the Company paid a member of its Board of Directors $62,500 and $150,000, respectively, for consulting services unrelated to their duties as board members. During the years ended April 30, 2015 and 2014, the Company paid a board member’s company $3,700 and $15,800, respectively, for consulting services. All of the amounts paid to these related parties have been recognized in expense in the period the services were performed. Private Placement During the year ended April 30, 2015, the Company sold an aggregate of 451,754 shares of common stock at a price of $4.80 per share and warrants to purchase an aggregate of 248,460 additional shares of common stock at an exercise price of $5.76 per share to two of its officers and directors in the March 2015 Private Placement. The proceeds of this sale were from the convertible promissory notes that were entered into on December 1, 2014 between the Company and two of its executive officers as described further in Note 7 above.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended	12 Months Ended
	Jan. 31, 2016	Apr. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 5. Commitments and Contingencies Operating Leases As of January 31, 2016, we lease the following facilities under non-cancelable operating lease agreements: • One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as the Company’s corporate headquarters. The lease expires in November 2016. The Company recognized $64,000 of rental costs relative to this lease for each of the nine months ended January 31, 2016 and 2015, respectively. • 855 North Wolfe Street, Suite 619, Baltimore, Maryland 21205, which consists of laboratories and office space where the Company conducts operations related to its primary service offerings. This lease expires June 2016. The Company recognized $65,000 of rental costs relative to this lease for each of the nine months ended January 31, 2016 and 2015. • 57 Mohamed Sultan Road, Singapore, which served as office headquarters for Champions Oncology, Singapore. The lease expired in January 2015. The Company has not renewed this lease. The Company recognized nil and $4,000 of rental expense for the nine months ended January 31, 2016 and 2015, respectively. • 450 East 29 th Legal Matters The Company is not currently party to any legal matters to its knowledge. The Company is not aware of any other matters that would have a material impact on the Company’s financial position or results of operations. Registration Payment Arrangements The Company has entered into an Amended and Restated Registration Rights Agreement in connection with the March 2015 Private Placement and is discussed more fully in Note 7 in the Company’s Form 10-K for the fiscal year ended April 30, 2015. This Amended and Restated Registration Rights Agreement contains provisions that may call for the Company to pay penalties in certain circumstances. This registration payment arrangement primarily relates to the Company’s ability to file a registration statement within a particular time period, have a registration statement declared effective within a particular time period and to maintain the effectiveness of the registration statement for a particular time period. The Company does not believe it is probable that such penalty payments will be made and, accordingly, has not accrued for such potential penalties as of January 31, 2016.	Note 5. Commitments and Contingencies Operating Leases As of April 30, 2015, we lease the following facilities under non-cancelable operating lease agreements: • One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as the Company’s corporate headquarters. The lease expires in November 2016. The Company recognized $85,000 and $75,000 of rental costs relative to this lease for fiscal 2015 and 2014, respectively. • 855 North Wolfe Street, Suite 619, Baltimore, Maryland 21205, which consists of laboratories and office space where the Company conducts operations related to its primary service offerings. This lease expires in June 2016. The Company recognized $86,000 and $85,000 of rental costs relative to this lease for fiscal 2015 and 2014, respectively. • 17 Hatidhar Street, Ra’anana, Israel, which serves as office headquarters for Champions Oncology, Israel. The Company recognized nil and $6,000 of rental costs relative to this lease for fiscal 2015 and 2014, respectively. Following the expiration of this lease, the Company utilizes office space on a limited basis from one of its stockholders. The fair value of rental costs associated with the new office space is immaterial. • 57 Mohamed Sultan Road, Singapore, which serves as office headquarters for Champions Oncology, Singapore. The lease expired in January 2015. The Company has not renewed this lease. The Company recognized $4,000 and $5,000 of rental costs relative to this lease for fiscal 2015 and 2014, respectively. • 450 East 29 th Future minimum lease payments due each fiscal year are as follows (in thousands): 2017 $ 192,013 2018 64,149 2019 — Total $ 256,162 Legal Matters The Company is not currently party to any legal matters to its knowledge. The Company is not aware of any other matters that would have a material impact on the Company’s financial position or results of operations. Registration Payment Arrangements The Company has entered into an Amended and Restated Registration Rights Agreement in connection with the March 2015 Private Placement and is discussed more fully in Note 7 below. This Amended and Restated Registration Rights Agreement contains provisions that may call for the Company to pay penalties in certain circumstances. This registration payment arrangement primarily relates to the Company’s ability to file a registration statement within a particular time period, have a registration statement declared effective within a particular time period and to maintain the effectiveness of the registration statement for a particular time period. The Company does not believe it is probable that penalty payments will be made for the Amended and Restated Registration Rights Agreement discussed in Note 7 and, accordingly, has not accrued for such potential penalties as of April 30, 2015 and 2014.

Teva Agreement

Teva Agreement	9 Months Ended	12 Months Ended
	Jan. 31, 2016	Apr. 30, 2015
Teva Agreement [Abstract]
Teva Agreement [Text Block]	Note 6. Teva Agreement On July 30, 2013, the Company entered into an agreement with Teva Pharmaceutical Industries Ltd. (“Teva”), pursuant to which the Company agreed to conduct TumorGraft studies on multiple proprietary chemical compounds provided by Teva to determine the activity or response of these compounds in potential clinical indications. Under the agreement, Teva agreed to pay an upfront payment and, under certain conditions, pay the Company various amounts upon achieving certain milestones, based on the performance of the compounds in preclinical testing and dependent upon testing the compound in clinical settings and obtaining FDA approval. In addition, Teva agreed to pay the Company royalties on any commercialized products developed under the agreement. This agreement terminated a prior collaborative agreement between Cephalon, Inc., a wholly-owned subsidiary of Teva, and the Company. Revenue recognized related to this agreement for the nine months ended January 31, 2016 and 2015, was $48,000 and $574,000, respectively.	Note 3. Teva Agreement On July 30, 2013, the Company entered into an agreement with Teva Pharmaceutical Industries Ltd., pursuant to which the Company agreed to conduct TumorGraft studies on multiple proprietary chemical compounds provided by Teva to determine the activity or response of these compounds in potential clinical indications. Under the agreement, Teva agreed to pay an upfront payment and, under certain conditions, pay the Company various amounts upon achieving certain milestones, based on the performance of the compounds in preclinical testing and dependent upon testing the compound in clinical settings and obtaining FDA approval. In addition, Teva agreed to pay the Company royalties on any commercialized products developed under the agreement. This agreement terminated a prior collaborative agreement between Cephalon, Inc. a wholly-owned subsidiary of Teva, and the Company. For the years ended April 30, 2015 and 2014, revenue of $724,000 and $194,000, respectively, were recognized relating to this agreement.

Fair Value

Fair Value	9 Months Ended
	Jan. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Note 7. Fair Value The carrying value of cash and cash equivalents, accounts receivable, deposits and other receivables, accounts payable, and accrued liabilities approximate their fair value based on the liquidity or the short-term maturities of these instruments. The fair value hierarchy promulgated by GAAP consists of three levels: • Level one • Level two • Level three Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company currently has no assets or liabilities measured at fair value on a recurring basis.

Common Stock and Stock Purchase

Common Stock and Stock Purchase Warrants	12 Months Ended
	Apr. 30, 2015
Common Stock and Stock Purchase Warrant [Abstract]
Common Stock and Stock Purchase Warrant [Text Block]	On January 28, 2013, the Company entered into a Securities Purchase Agreement with several accredited investors for the sale of an aggregate 1,550,000 shares of the Company’s Common Stock at a purchase price of $6.00 per share, for aggregate proceeds of $9.3 million (net proceeds of $9.1 million due to issuance costs), $0.5 million of which was sold to officers and directors of the Company. This private placement transaction closed on January 28, 2013 (the “January 2013 Private Placement”). As part of this transaction, the Company also issued warrants to purchase an aggregate 155,000 shares of Common Stock at an exercise price of $7.92 per share. These warrants expire five years after the closing date. The Company also entered into an Amended and Restated Registration Rights Agreement on January 28, 2013 that provided certain registration rights with respect to the shares of Common Stock issued and the shares of Common Stock issuable upon exercise of the warrants. Furthermore, certain investors will have the right to require the Company to redeem the purchased common shares held by all of the investors (the “January 2013 Private Placement Put Option”) for cash of $6.00 per share upon a change of control or sale or exclusive license of substantially all of the Company’s assets. The January 2013 Private Placement Put Option will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities Purchase Agreement for the January 2013 Private Placement. The January 2013 Private Placement investors also have certain participation rights with respect to future financings of the Company. The terms of the January 2013 Private Placement resulted in the issuance of an additional 88,722 common shares to the investors of the April 2011 Private Placement under the anti-dilution protections granted such investors, which are discussed below. On March 24, 2011, the Company entered into a Securities Purchase Agreement with several accredited investors for the sale of an aggregate 1,044,444 shares of the Company’s Common Stock at a purchase price of $9.00 per share, for aggregate proceeds of $9.4 million, $0.5 million of which was sold to officers and directors of the Company. This private placement transaction closed April 4, 2011 (the “April 2011 Private Placement”). As part of this transaction, the Company also issued warrants to purchase an aggregate 105,556 shares of Common Stock at an exercise price of $10.80 per share. These warrants expire five years after the closing date. The Securities Purchase Agreement governing the April 2011 Private Placement contains certain anti-dilution protections for the investors. The Amended and Restated Registration Rights Agreement referenced above provides certain registration rights with respect to the shares of Common Stock issued and the shares of Common Stock issuable upon exercise of the warrants. Furthermore, certain investors have the right to require the Company to redeem the purchased common shares held by all of the investors (the “April 2011 Private Placement Put Option”) for cash for $9.00 per share upon a change of control or sale or exclusive license of substantially all of the Company’s assets. The April 2011 Private Placement Put Option will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities Purchase Agreement for the April 2011 Private Placement. Due to the April 2011 Private Placement Put Option and the January 2013 Private Placement Put Option described above, the Company has accounted for the Common Stock for the April 2011 Private Placement and January 2013 Private Placement as temporary equity, which is reflected under the caption “redeemable common stock” on the accompanying consolidated balance sheets for 2013. The total amount allocated to the redeemable common stock was $8.8 million for the January 2013 Private Placement and $8.2 million for the April 2011 Private Placement. For the January 2013 Private Placement, this allocation is equal to the total proceeds of $9.3 million less the amount allocated to the warrants of $0.4 million and is also net of the direct and incremental costs associated with the January 2013 Private Placement of $0.2 million. For the April 2011 Private Placement, this allocation is equal to the total proceeds of $9.4 million, less the amount allocated to the warrants of $0.9 million and is also net of direct and incremental costs associated with the April 2011 Private Placement of $0.3 million. On January 29, 2014, the Company executed amendments to existing securities purchase agreements entered into during 2011 and 2013 (collectively the “2011 Securities Purchase Agreement” and the “2013 Securities Purchase Agreement”) with certain of the parties thereto, in each case revising the definition of “Change of Control” as it appears on the Securities Purchase Agreements, to eliminate rights to redeem shares of common stock purchased under these arrangements. Such common stock which was classified in the mezzanine section as redeemable common stock as a result of these provisions was re-classified as equity. On January 29, 2014, the Company also entered into an agreement with Joel Ackerman, its Chief Executive Officer and a Director, and Ronnie Morris, its President and a Director, both of whom bought securities from the Company pursuant to the Securities Purchase Agreements, that, if the Company’s Board of Directors votes on a transaction, event or approval that would constitute a Put Option Trigger Event (as defined in each of the Securities Purchase Agreements), each of Ackerman and Morris shall either (a) recuse themselves from voting as a member of the Board of Directors on such transaction, event or approval or (b) be entitled to vote but forego exercising or receiving the benefit of their Put Right (as defined in each of the Securities Purchase Agreements). Prior to the January 29, 2014 amendments the Put Option Trigger Event (as defined in each of the Securities Purchase Agreements) was outside of the Company’s control. Subsequent to the January 29, 2014 amendments the Put Option Trigger Event is within the Company’s control. This change resulted in the common stock related to the April 2011 Private Placement and the 2013 Private Placement to be reclassified from outside of permanent equity (reflected under the caption “redeemable common stock”) to inside permanent equity (reflected in the captions “common stock” and “additional paid-in capital”) for 2014. The warrants issued in connection with both the April 2011 Private Placement and January 2013 Private Placement contained certain exercise price reset provisions. Under these provisions, the exercise price of the warrants may be adjusted downward should the Company have future sales of its Common Stock for no consideration or for a consideration per share less than the Per Share Price (as such term is defined in the April 2011 Private Placement and January 2013 Private Placement). These exercise price reset provisions resulted in a downward adjustment to the exercise price of the warrants issued in the April 2011 Private Placement from $10.80 to $6.00 in January 2013 as part of the 2013 Private Placement. On December 1, 2014, the Company entered into note purchase agreements with and issued convertible promissory notes in the principal amount of $1 million each to Joel Ackerman, the Company’s Chief Executive Officer, and Dr. Ronnie Morris, the Company’s President, to finance the operations of the Company. The transaction was approved by the Company’s audit committee. The notes bore interest at 12% per annum and had an initial term of 90 days. The notes, including any accrued but unpaid interest, were convertible at the option of each noteholder: (a) upon the closing of any equity financing that occurred during the term of the notes, into the securities offered in the financing to other investors at a 5% discount to the price per share paid by other investors in the financing; and (b) upon the maturity date of the notes, into the Company’s common stock at the volume weighted average closing price of the common stock for the five trading days prior to such conversion. On February 28, 2015, the Company entered into amendments to the convertible promissory notes issued on December 1, 2014. The amendments extended the maturity dates of the convertible promissory notes to April 1, 2015. The amendments were approved by the Company’s audit committee. On March 11, 2015, the convertible promissory notes and accrued interest of $60,000 were converted into equity at a 5% discount as part of the 2015 Securities Purchase Agreement. The 5% discount was contingent up until the closing of the 2015 Securities Purchase Agreement at which time the 5% discount was converted to an amount of $100,000 and classified into equity along with the $60,000 accrued interest noted above. On March 11, 2015, the Company entered into a Securities Purchase Agreement (the “2015 Securities Purchase Agreement”) with Battery Ventures IX, L.P. and Battery Investment Partners IX, LLC (collectively, “Battery”), New Enterprise Associates 14, Limited Partnership (“NEA”), Joel Ackerman, Chief Executive Officer and a director of the Company (“Ackerman”), Dr. Ronnie Morris, President and a director of the Company (“Morris”), Daniel Mendelson, a director of the Company (“Mendelson”) and certain other investors (collectively with Battery, NEA, Ackerman, Morris and Mendelson, the “Investors”), for the sale to the Investors of units, each unit consisting of one share of the Company’s Common Stock, par value $0.001 per share (the “Common Stock”) and a warrant to buy 0.55 shares of Common Stock at $5.76 per share (the “Warrants”), at a purchase price of $4.80 per unit, for an aggregate of $14,000,000. The Warrants expire five years after the closing date. Ackerman and Morris converted convertible promissory notes dated December 1, 2014 in the principal amounts of $1 million each, plus accrued interest, into the units at a 5% discount, pursuant to the terms of the convertible promissory notes. The Company has accounted for the Common Stock for the March 2015 Private Placement as equity on the accompanying consolidated balance sheets for 2015. The amount allocated to common stock was $8.0 million. This allocation is equal to the total proceeds of $14 million less the amount allocated to warrants of $5.1 million and is also net of the direct and incremental costs associated with the 2015 Private Placement of $0.88 million. The Black Scholes pricing model was used to calculate the value of warrants relating to the 2015 Securities Purchase Agreement. The Investors have the right to require the Company to repurchase the purchased shares (the “Put Option”) for cash for $4.80 per share upon a change of control or sale or exclusive license of substantially all of the Company’s assets only if approved by the Company’s board of directors. The Put Option will terminate upon the achievement of certain financial and other milestones. The Investors have certain participation rights with respect to future financings of the Company. The Company covenanted to register the resale of the shares of Common Stock to be issued to the Investors and the shares of Common Stock issuable upon exercise of the Warrants pursuant to a 2015 Amended and Restated Registration Rights Agreement, to pay certain liquidated damages if the Company fails to file such registration statement by a certain deadline, and to have it declared effective by a certain deadline or keep it effective for a certain period of time. The Company has not accrued any liquidated damages associated with the Amended and Restated Registration Right Agreement as the Company has filed the required registration statement and anticipates continued compliance with the agreement. The issuance of the shares of Common Stock resulted in the Company issuing an additional 188,704 shares of Common Stock to investors who purchased shares of Common Stock pursuant to a Securities Purchase Agreement dated as of March 24, 2011 (the “2011 Securities Purchase Agreement”) due to contractual antidilution provisions in that 2011 Securities Purchase Agreement. The Company also amended and restated the 2011 Securities Purchase Agreement to eliminate these antidilution provisions going forward, and conform aspects of the put option in that 2011 Securities Purchase Agreement to terms of the Put Option in the 2015 Securities Purchase Agreement. The Company also issued an additional 131,945 warrants to its investors under the antidilution provision of 2011 Warrant Agreements under the Securities Purchase Agreement. Concurrently its investors agreed on certain amendments of the warrants to eliminate the antidilution rights for future transactions, by extending the term of the warrants by one year, and adjusting the exercise price to $4.80 as an incentive to remove the antidulution rights. This resulted in a modification charge of $413,521. The Company and its investors have amended and restated its Securities Purchase Agreement dated January 28, 2013 (the “2013 Securities Purchase Agreement”) to conform aspects of the put option in that 2013 Securities Purchase Agreement to the Put Option in the 2015 Securities Purchase Agreement. The Company issued an additional 100,750 warrants to investors under the antidilution provision of 2013 Warrant Agreements under the Securities Purchase Agreement. Concurrently its investors agree on certain amendments of these warrants to eliminate the antidilution rights for future transactions, by extending the term of the warrant by one year and adjusting the exercise price to $4.80 as an incentive to remove the antidilution rights. This resulted in a modification charge of $172,344. On April 24, 2015, the Company filed an amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware, which increased the total number of shares of common stock the Company is authorized to issue to 200,000,000 from 125,000,000. The Company had accounted for the warrants issued in connection with the April 2011 Private Placement and January 2013 Private Placement as a liability based on the exercise price reset provisions described above. This liability, which was recorded at fair value on the accompanying consolidated balance sheets, totaled $1.6 million at the time of the close of the March 2015 Private Placement Agreement. Due to the amendments noted above, the liability has been reclassified to equity as shown in note 1 above. As of April 30, 2015 and 2014, the fair value of these warrants was nil and $2.01 million, respectively. The change in fair value of these warrants prior to the amendments noted above was recognized as other income (expense) on the Company’s consolidated statements of operations. The fair value of these warrants was calculated by the Monte Carlo simulation valuation method. Year Ended April 30, 2015 2014 Expected term in years 1.1 – 4.9 1.9 – 3.7 Risk-free interest rates 0.5% – 1.76% 0.4% – 1.17% Volatility 73% – 107% 95% – 113% Dividend yield 0% 0% The Company estimated the volatility based upon the applicable look-back periods or historical volatility observed for the Company. For the Risk-free rate the Company used the yield on a T-bill with maturity closest to the expected time to the warrant expiration. In addition to the assumptions above, the Company also took into consideration the probability of the Company’s participation in another round of financing, the type of such financing and the range of the stock price for the financing at that time.

Provision for Income Taxes

Provision for Income Taxes	12 Months Ended
	Apr. 30, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Year Ended April 30, 2015 Federal State Foreign Total Current $ — $ 3 $ 124 $ 127 Deferred (25,948 ) (1,771 ) 8 (27,711 ) Change in valuation allowance 25,948 1,771 (8 ) 27,711 Total $ — $ 3 $ 124 $ 127 Year Ended April 30, 2014 Federal State Foreign Total Current $ — $ 5 $ 12 $ 17 Deferred (2,015 ) (148 ) — (2,163 ) Change in valuation allowance 2,015 148 — 2,163 Total $ — $ 5 $ 12 $ 17 Year Ended April 30, 2015 2014 Federal income tax at statutory rate 34.0 % 34.0 % State income tax, net of federal benefit 2.6 2.1 Permanent differences 0.9 (5.6 ) Increase in uncertain tax position (0.8 ) — Other (6.9 ) (2.1 ) Change in valuation allowance (30.8 ) (27.2 ) Changes in tax rates — (1.4 ) Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. As of April 30, 2015 2014 Accrued liabilities $ 21 $ 38 Depreciation and amortization — 9 State taxes 1 1 Stock-based compensation expense 4,803 4,511 Capitalized research and development costs 433 556 Foreign net operating loss carry-forward 235 244 Net operating loss carry-forward 9,719 5,608 Total deferred tax assets 15,212 10,968 Less: Valuation allowance (15,212 ) (10,968 ) Net deferred tax asset $ — $ — Management has evaluated the available evidence about future tax planning strategies, taxable income and other possible sources of realization of deferred tax assets and has established a full valuation allowance against its net deferred tax assets as of April, 30, 2015 and 2014. For the years ended April 30, 2015 and 2014, the Company recorded a valuation allowance of $14.9 million and $11.0 million, respectively. As of April 30, 2015 and 2014, the Company’s estimated U.S. net operating loss carry-forwards were approximately $26 million and $15 million, respectively, which will begin expiring in 2022 for federal and 2017 for state purposes. As of April 30, 2015 and 2014, the Company’s foreign net operating loss carry-forward was approximately $1million for both periods, respectively, which have an unlimited carryforward period. A valuation allowance has been recorded against all of these losses due to continued overall losses. The Company may be subject to the net operating loss provisions of Section 382 of the Internal Revenue Code. Due to the company’s funding transaction, the company may have triggered a net operating loss limitation under Internal Revenue Code §382. The company has not calculated if an ownership change has occurred. The effect of an ownership change would be the imposition of an annual limitation on the use of NOL carryforwards attributable to periods before the change. The amount of the annual limitation depends upon the value of the Company immediately before the change, changes to the Company’s capital during a specified period, and the federal published interest rate. The Company has made no provision for U.S. taxes on the cumulative earnings of foreign subsidiaries as those earnings are intended to be reinvested for an indefinite period of time. Upon distribution of these earnings in the form of dividends or otherwise, the Company may be subject to U.S. income taxes and foreign withholding taxes. It is not practical, however, to estimate the amount of taxes that may be payable on the eventual repatriation of these earnings. The Company files income tax returns in various jurisdictions with varying statues of limitations. As of April 30, 2015, the earliest tax year still subject to examination for state purposes is fiscal 2012. The Company’s tax years for periods ending April 30, 2001 and forward are subject to examination by the United States and certain states due to the carry-forward of unutilized net operating losses. Year Ended April 30, 2015 2014 Balance, beginning of the year $ — $ — Addition based on tax positions related to prior years 21 — Addition based on tax positions related to current year 79 — Balance, end of year $ 100 $ — As of April 30, 2015 the above amount of $100,000 was included in other long-term liabilities.

Segment Information

Segment Information	9 Months Ended	12 Months Ended
	Jan. 31, 2016	Apr. 30, 2015
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	Note 8. Segment Information The Company operates in two reportable segments, POS and TOS. The accounting policies of the Company’s segments are the same as those described in Note 2 of the Company’s annual financial statements for the year ended April 30, 2015, as filed on Form 10-K. The Company evaluates performance of its segments based on profit or loss from operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes (“segment profit”). Management uses segment profit information for internal reporting and control purposes and considers it in making decisions regarding the allocation of capital and other resources, risk assessment, and employee compensation, among other matters. Three Months Ended January 31, 2016 Personalized Translational Unallocated Consolidated Net revenue $ 416 $ 2,136 $ — $ 2,552 Direct cost of services (479 ) (1,624 ) — (2,103 ) Sales and marketing costs (183 ) (569 ) — (752 ) Other operating expenses — (950 ) (553 ) (1,503 ) Stock-based compensation expense (1) — — (567 ) (567 ) Segment profit (loss) $ (246 ) $ (1,007 ) $ (1,120 ) $ (2,373 ) Three Months Ended January 31, 2015 Personalized Translational Unallocated Consolidated Net revenue $ 453 $ 1,376 $ — $ 1,829 Direct cost of services (672 ) (1,300 ) — (1,972 ) Sales and marketing costs (366 ) (613 ) — (979 ) Other operating expenses — (1,028 ) (612 ) (1,640 ) Stock-based compensation expense (1) — — (657 ) (657 ) Segment profit (loss) $ (585 ) $ (1,565 ) $ (1,269 ) $ (3,419 ) Nine Months Ended January 31, 2016 Personalized Translational Unallocated Consolidated Net revenue $ 1,387 $ 6,958 $ — $ 8,345 Direct cost of services (1,634 ) (4,654 ) — (6,288 ) Sales and marketing costs (716 ) (1,800 ) — (2,516 ) Other operating expenses — (2,755 ) (2,463 ) (5,218 ) Stock-based compensation expense (1) — — (2,090 ) (2,090 ) Segment profit (loss) $ (963 ) $ (2,251 ) $ (4,553 ) $ (7,767 ) Nine Months Ended January 31, 2015 Personalized Translational Unallocated Consolidated Net revenue $ 1,245 $ 4,377 $ — $ 5,622 Direct cost of services (2,171 ) (3,205 ) — (5,376 ) Sales and marketing costs (1,243 ) (1,650 ) — (2,893 ) Other operating expenses — (3,490 ) (2,413 ) (5,903 ) Stock-based compensation expense (1) — — (2,284 ) (2,284 ) Segment profit (loss) $ (2,169 ) $ (3,968 ) $ (4,697 ) $ (10,834 ) (1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments. All of the Company’s revenue is recorded in the United States and substantially all of its long-lived assets are in the United States.	Note 10. Business Segment Information The Company operates in two segments, POS and TOS. The accounting policies of the Company’s segments are the same as those described in Note 2. The Company evaluates performance of its segments based on profit or loss from operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes (“segment profit”). Management uses segment profit information for internal reporting and control purposes and considers it important in making decisions regarding the allocation of capital and other resources, risk assessment, and employee compensation, among other matters. Year Ended April 30, 2015 Personalized Translational Unallocated Consolidated Net revenue $ 1,663 $ 7,200 $ — $ 8,863 Direct cost of services (2,711 ) (4,877 ) — (7,588 ) Sales and marketing costs (1,514 ) (2,208 ) — (3,722 ) Other operating expenses — (4,493 ) (3,136 ) (7,729 ) Stock compensation expense (1) — — (3,162 ) (3,162 ) Segment profit (loss) $ (2,562 ) $ (4,378 ) $ (6,298 ) $ (13,238 ) Year Ended April 30, 2014 Personalized Translational Unallocated Consolidated Net revenue $ 2,264 $ 9,286 $ — $ 11,550 Direct cost of services (2,667 ) (3,496 ) — (6,163 ) Sales and marketing costs (1,723 ) (1,080 ) — (2,803 ) Other operating expenses — (2,209 ) (3,828 ) (6,037 ) Stock compensation expense (1) — — (2,807 ) (2,807 ) Segment loss $ (2,126 ) $ 2,501 $ (6,635 ) $ (6,260 ) (1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments. All of the Company’s revenue is recorded in the United States and substantially all of its long-lived assets are in the United States.

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Apr. 30, 2015
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation. The Company’s foreign subsidiaries functional currency is the U.S. dollar. Transaction gains and losses are recognized in earnings. The Company is subject to foreign exchange rate fluctuations in connection with the Company’s international operations.
Use of Estimates, Policy [Policy Text Block]	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	The Company considers all highly liquid investments purchased with a maturity of three months or less at the time of purchase, to be cash equivalents. At various times, the Company has amounts on deposit at financial institutions in excess of federally insured limits.
Fair Value Measurement, Policy [Policy Text Block]	The carrying value of cash and cash equivalents, accounts receivable, prepaid expenses, deposits and other receivables, accounts payable, and accrued liabilities approximate their fair value based on the liquidity or the short-term maturities of these instruments. The fair value hierarchy promulgated by GAAP consists of three levels: · Level one · Level two · Level three Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company had one liability measured at fair value on a recurring basis, which relate to warrants that were issued in connection with the 2011 and 2013 private placements of the Company’s securities. On March 11, 2015 the Company entered into a securities purchase agreement and amended certain agreements which eliminated the provisions within the warrant agreements requiring the liability classification of the warrant liability. Accordingly, the warrant liability was reclassified to equity at the date of such modification which is discussed more fully in Note 7. As of March 11, 2015 and April 30, 2014, these warrants had an estimated fair value of $ 1.6 2 2015 2014 Balance beginning of year $ (2,011) $ (1,046) Transfers to (from) Level 3 — — Change in fair value included in earnings 981 (965) Modification Charge (586) Reclassification to equity 1,616 — Balance end of year $ — $ (2,011)
Trade and Other Accounts Receivable, Policy [Policy Text Block]	Accounts receivable represent amounts due under agreements with pharmaceutical and biotechnology companies for TOS and amounts due under agreements with patients for POS. At each reporting period, the Company evaluates open accounts receivable for collectability and records an allowance for potentially uncollectible accounts. For both April 30, 2015 and 2014, the allowance for these accounts was $ 2,000 636,000 884,000
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	As of April 30, 2015 and 2014, the Company has restricted cash of $ 163,000 165,000
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment is recorded at cost and primarily consists of laboratory equipment, furniture and fixtures, and computer hardware and software. Depreciation and amortization is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from three to seven years. April 30, 2015 2014 Furniture and fixtures $ 70 $ 69 Computer equipment and software 685 655 Laboratory equipment 493 296 Leasehold improvements 2 2 Total property and equipment 1,250 1,022 Less: Accumulated depreciation and amortization (798) (588) Property and equipment, net $ 452 $ 434 Depreciation and amortization expense was $ 214,000 213,000 124,000 12,405
Lease, Policy [Policy Text Block]	In November 2014, the Company entered into a lease for laboratory equipment. The lease is a capital lease that has costs of approximately $ 149,000 3,000 For the Years Ended April 30, 2016 23 2017 24 2018 25 2019 26 2020 16 Total minimum lease payments $ 114 Less: current maturity (23) Long-term maturity 91 The present value of minimum future obligations shown above is calculated based on interest rate of 5
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment losses are to be recognized when the carrying amount of a long-lived asset is not recoverable or exceeds its fair value. The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that a carrying value may not be recoverable. The Company uses estimates of future cash flows over the remaining useful life of a long-lived asset or asset group to determine the recoverability of the asset. These estimates only include the net cash flows directly associated with, and that are expected to arise as a direct result of, the use and eventual disposition of the asset or asset group. The Company has not recognized any impairment losses for the Company’s long-lived assets for the years ending April 30, 2015 and 2014.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Goodwill represents the excess of the cost over the fair market value of the net assets acquired including identifiable assets. Goodwill is tested annually, or more frequently if circumstances indicate potential impairment, by comparing its fair value to its carrying amount. The determination of whether or not goodwill is impaired involves significant judgment. Although the Company believes its goodwill is not impaired, changes in strategy or market conditions could significantly impact the judgments and may require future adjustments to the carrying value of goodwill. The Company uses a two-step process to test for goodwill impairment. The first step is to screen for potential impairment, while the second step measures the amount of the impairment, if any. The first step of the goodwill impairment test compares the fair value of each reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying value, goodwill is not impaired. If the carrying value of the reporting unit’s net assets, including goodwill, exceeds the fair value of the reporting unit, then the Company determines the implied fair value of goodwill. If the carrying value of goodwill exceeds its implied fair value, then an impairment of goodwill has occurred and an impairment loss would be recognized for the difference between the carrying amount and the implied fair value of goodwill as a component of operating income. The implied fair value of goodwill is calculated by subtracting the fair value of tangible and intangible assets associated with the reporting unit from the fair value of the unit. The Company tests for goodwill impairment at the operating segment level. The Company has not recognized any impairment losses for the Company’s goodwill for the years ending April 30, 2015 and 2014.
Revenue Recognition, Deferred Revenue [Policy Text Block]	Deferred revenue represents payments received in advance for products to be delivered. When products are delivered, deferred revenue is then recognized as earned.
Warrant Liability [Policy Text Block]	Warrant liability represented the fair value of warrants issued in connection with the 2011 and 2013 private placements of the Company’s common stock, which are described more fully in Note 8. These warrants were presented as liabilities based on the certain exercise price reset provisions. The liability, which was recorded at fair value on the accompanying consolidated balance sheets, was calculated by the Monte Carlo simulation valuation method. The change in fair value of these warrants were recognized as other income or expense in the consolidated statements of operations. On March 11, 2015 the Company entered into a securities purchase agreement and amended the 2011 and 2013 warrant agreements which eliminated the liability feature of these warrants. Such warrants were transferred to equity which is discussed more fully in Note 7.
Revenue Recognition, Policy [Policy Text Block]	The Company derives revenue from its POS and TOS businesses. Personalized oncology solutions assist physicians by providing information to help guide the development of personalized treatment plans for their patients using our core offerings, including testing oncology drugs and drug combinations on personalized TumorGrafts, and through other products. Translational oncology solutions offer a preclinical TumorGraft platform to pharmaceutical and biotechnology companies using proprietary TumorGraft studies, which the Company believes may be predictive of how drugs may perform in clinical settings. The Company recognizes revenue when the following four basic criteria are met: (i) a contract has been entered into with its customers; (ii) delivery has occurred or services rendered to its customers; (iii) the fee is fixed and determinable as noted in the contract; and (iv) collectability is reasonably assured. The Company utilizes a proportional performance revenue recognition model for its TOS business, under which it recognizes revenue as performance occurs, based on the relative outputs of the performance that have occurred up to that point in time under the respective agreement, typically the delivery of reports to its customers documenting the results of testing protocols. When a POS or TOS arrangement involves multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent separate units of accounting. The Company performs this evaluation at the inception of an arrangement and as each item in the arrangement is delivered. Generally, the Company accounts for a deliverable (or a group of deliverables) separately if: (i) the delivered item(s) has standalone value to the customer, and (ii) if the Company has given the customer a general right of return relative to the delivered item(s) and the delivery or performance of the undelivered item(s) or service(s) is probable and substantially in the Company’s control. All revenue from contracts determined not to have separate units of accounting is recognized based on consideration of the most substantive delivery factor of all the elements in the contract or if there is no predominant deliverable upon delivery of the final element of the arrangement. During the third quarter of fiscal year 2014 we entered into a contract that may require the replacement of licensed tumors in the event that certain contractual terms have not been satisfied. Due to such requirements we have estimated an amount of licensed tumors that may need to be replaced, and we have deferred this revenue until all provisions of the agreement have been met. There was $ 258,000
Cost Of Personalized Oncology Solutions [Policy Text Block]	Cost of POS consists of costs related to POS revenue earned from implantations, drug panels, tumor boards, and gene sequencing services, as well as indirect internal costs, such as salaries for personnel directly engaged in these products. Direct costs associated with implantation revenues are primarily related to mice purchases and maintenance and shipping of tumor tissue. Direct drug panel costs are primarily incurred from mice purchases and maintenance and drug purchases. Direct tumor board costs are primarily related to physicians’ honorariums and any tumor board participation costs such as travel, lodging and meals. Direct gene sequencing costs are primarily related to costs billed from the gene sequencing service provider. All costs are expensed as incurred.
Cost Of Translational Oncology Solutions [Policy Text Block]	Cost of TOS consists of costs related to TOS revenue. Direct costs include mice purchases and maintenance costs for studies completed internally and charges from CROs for studies handled externally. Indirect costs include salaries for personnel directly engaged in providing TOS products. All costs of performing studies in-house are expensed as incurred. All costs of performing studies from external sources, if any, are expensed when received.
Research and Development Expense, Policy [Policy Text Block]	Research and development costs represent both costs incurred internally for research and development activities, including personnel costs and mice purchases and maintenance, as well as costs incurred externally to facilitate research activities, such as tumor tissue procurement and characterization expenses. All research and development costs are expensed as incurred.
Cost of Sales, Policy [Policy Text Block]	Selling and marketing expenses represent costs incurred to promote the Company’s products offered, including salaries, benefits and related costs of our sales and marketing personnel, and represent costs of advertising and other selling and marketing expenses. All sales and marketing costs, including advertising costs, are expensed as incurred.
Earnings Per Share, Policy [Policy Text Block]	Basic net loss per share is computed by dividing the net loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss for the period by the weighted-average number of shares of common stock plus dilutive potential common stock considered outstanding during the period. Such dilutive shares consist of incremental shares that would be issued upon exercise of the Company’s derivative warrants, which were reclassified to equity as discussed in note 7. Year Ended April 30, 2015 2014 Basic loss per share computation Net loss attributable to common stockholders $ (13,139,820) $ (7,406,367) Weighted Average common shares – basic 5,985,346 5,571,993 Basic net loss per share $ (2.20) $ (1.33) Diluted loss per share computation Net loss attributable to common stockholders $ (13,139,820) $ (7,406,367) Less: Gain on derivative warrant liability 980,519 — Loss available to common stockholders $ (14,120,339) $ (7,406,367) Weighted Average common shares 5,985,346 5,571,993 Incremental shares from assumed exercise of warrants and stock options 439,065 — Adjusted weighted average share – diluted 6,424,410 5,571,993 Diluted net loss per share $ (2.20) $ (1.33) Year Ended April 30, 2015 2014 Stock options 2,004,002 1,945,920 Warrants 2,109,840 273,056 Total common stock equivalents 4,113,842 2,218,975
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	The Company typically recognizes expense for share-based payments based on the fair value of awards on the date of grant. The Company uses the Black-Scholes option pricing model to estimate fair value. The Black-Scholes option valuation model was developed for use in estimating the fair value of short-traded options that have no vesting restrictions and are fully transferable. The option pricing model requires the Company to estimate certain key assumptions such as expected life, volatility, risk free interest rates and dividend yield to determine the fair value of share-based awards. These assumptions are based on historical information and management judgment. The risk-free interest rate used is based on the United States treasury security rate with a term consistent with the expected term of the award at the time of the grant. Since the Company has limited option exercise history, it has generally elected to estimate the expected life of an award based upon the Securities and Exchange Commission-approved “simplified method” noted under the provisions of Staff Accounting Bulletin No. 107 with the continued use of this method extended under the provisions of Staff Accounting Bulletin No. 110. The Company expenses share-based payments over the period that the awards are expected to vest, net of estimated forfeitures. If actual forfeitures differ from management’s estimates, compensation expense is adjusted. The Company expenses modification charges in the period of modification and, if required, over the remaining period the awards are expected to vest. The Company will report cash flows resulting from tax deductions in excess of the compensation cost recognized from those options (excess tax benefits) as financing cash flows, if they should arise.
Income Tax, Policy [Policy Text Block]	Deferred income taxes have been provided to show the effect of temporary differences between the recognition of expenses for financial and income tax reporting purposes and between the tax basis of assets and liabilities, and their reported amounts in the consolidated financial statements. In assessing the realizability of deferred tax assets, the Company assesses the likelihood that deferred tax assets will be recovered through tax planning strategies or from future taxable income, and to the extent that recovery is not likely or there is insufficient operating history, a valuation allowance is established. The Company adjusts the valuation allowance in the period management determines it is more likely than not that net deferred tax assets will or will not be realized. Changes in valuation allowances from period to period are included in the tax provision in the period of change. As of April 30, 2015 and 2014, the Company provided a valuation allowance for all net deferred tax assets, as recovery is not more likely than not based on an insufficient history of earnings. Tax positions are positions taken in a previously filed tax return or positions expected to be taken in a future tax return that are reflected in measuring current or deferred income tax assets and liabilities reported in the consolidated financial statements. Tax positions include, but are not limited to, the following: · An allocation or shift of income between taxing jurisdictions; · The characterization of income or a decision to exclude reportable taxable income in a tax return; or · A decision to classify a transaction, entity or other position in a tax return as tax exempt. The Company reflects tax benefits only if it is more likely than not that we will be able to sustain the tax position, based on its technical merits. If a tax benefit meets this criterion, it is measured and recognized based on the largest amount of benefit that is cumulatively greater than 50% likely to be realized. The Company has $ 100 The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties on the Company’s balance sheets at April 30, 2015 and 2014, and has not recognized interest and/or penalties in the statement of operations for either period. We do not anticipate any significant unrecognized tax benefits will be recorded during the next 12 months.
New Accounting Pronouncements, Policy [Policy Text Block]	In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers” In June 2014, FASB has issued Accounting Standards Update (“ASU”) No. 2014-12, “Compensation — Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period”. In August 2014, FASB issued Accounting Standards Update (“ASU”) 2014-15, “Presentation of Financial Statements — Going Concern: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”

Organization, Use of Estimate23

Organization, Use of Estimates and Basis of Presentation (Tables)	9 Months Ended	12 Months Ended
	Jan. 31, 2016	Apr. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Nine Months Ended 2016 2015 2016 2015 Basic loss per share computation Net loss attributable to common stockholders $ (2,412,381 ) $ (2,816,465 ) $ (7,872,115 ) $ (9,462,281 ) Weighted Average common shares – basic 8,702,237 5,574,447 8,702,237 5,574,244 Basic net loss per share $ (0.28 ) $ (0.51 ) $ (0.90 ) $ (1.70 ) Diluted loss per share computation Net loss attributable to common stockholders $ (2,412,381 ) $ (2,816,465 ) $ (7,872,115 ) $ (9,462,281 ) Less: Gain on derivative warrant liability — 620,687 — 1,401,314 Loss available to common stockholders $ (2,412,381 ) $ (3,437,152 ) $ (7,872,115 ) $ (10,863,595 ) Weighted Average common shares 8,702,237 5,574,447 8,702,237 5,574,244 Incremental shares from assumed exercise of warrants and stock options — 29,351 — 29,351 Adjusted weighted average share – diluted 8,702,237 5,603,798 8,702,237 5,603,595 Diluted net loss per share $ (0.28 ) $ (0.61 ) $ (0.90 ) $ (1.94 )	Year Ended April 30, 2015 2014 Basic loss per share computation Net loss attributable to common stockholders $ (13,139,820) $ (7,406,367) Weighted Average common shares – basic 5,985,346 5,571,993 Basic net loss per share $ (2.20) $ (1.33) Diluted loss per share computation Net loss attributable to common stockholders $ (13,139,820) $ (7,406,367) Less: Gain on derivative warrant liability 980,519 — Loss available to common stockholders $ (14,120,339) $ (7,406,367) Weighted Average common shares 5,985,346 5,571,993 Incremental shares from assumed exercise of warrants and stock options 439,065 — Adjusted weighted average share – diluted 6,424,410 5,571,993 Diluted net loss per share $ (2.20) $ (1.33)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	January 31, 2016 2015 Stock options 2,212,571 1,999,167 Warrants 2,109,840 260,556 Total common stock equivalents 4,322,411 2,259,723	Year Ended April 30, 2015 2014 Stock options 2,004,002 1,945,920 Warrants 2,109,840 273,056 Total common stock equivalents 4,113,842 2,218,975

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Tables)	9 Months Ended	12 Months Ended
	Jan. 31, 2016	Apr. 30, 2015
Accounting Policies [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]		2015 2014 Balance beginning of year $ (2,011) $ (1,046) Transfers to (from) Level 3 — — Change in fair value included in earnings 981 (965) Modification Charge (586) Reclassification to equity 1,616 — Balance end of year $ — $ (2,011)
Public Utility Property, Plant, and Equipment [Table Text Block]		April 30, 2015 2014 Furniture and fixtures $ 70 $ 69 Computer equipment and software 685 655 Laboratory equipment 493 296 Leasehold improvements 2 2 Total property and equipment 1,250 1,022 Less: Accumulated depreciation and amortization (798) (588) Property and equipment, net $ 452 $ 434
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	The following is a schedule by years of future minimum lease payments under this capital lease together with the present value of the net minimum lease payments as of January 31, 2016 (table in thousands): For the Years Ended April 30, Total 2016 (remaining) $ 6 2017 24 2018 25 2019 27 2020 16 Total minimum payments 98 Less: amount representing interest (10) Present value of minimum payments 88 Less: current portion (24) $ 64	For the Years Ended April 30, 2016 23 2017 24 2018 25 2019 26 2020 16 Total minimum lease payments $ 114 Less: current maturity (23) Long-term maturity 91
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Nine Months Ended 2016 2015 2016 2015 Basic loss per share computation Net loss attributable to common stockholders $ (2,412,381 ) $ (2,816,465 ) $ (7,872,115 ) $ (9,462,281 ) Weighted Average common shares – basic 8,702,237 5,574,447 8,702,237 5,574,244 Basic net loss per share $ (0.28 ) $ (0.51 ) $ (0.90 ) $ (1.70 ) Diluted loss per share computation Net loss attributable to common stockholders $ (2,412,381 ) $ (2,816,465 ) $ (7,872,115 ) $ (9,462,281 ) Less: Gain on derivative warrant liability — 620,687 — 1,401,314 Loss available to common stockholders $ (2,412,381 ) $ (3,437,152 ) $ (7,872,115 ) $ (10,863,595 ) Weighted Average common shares 8,702,237 5,574,447 8,702,237 5,574,244 Incremental shares from assumed exercise of warrants and stock options — 29,351 — 29,351 Adjusted weighted average share – diluted 8,702,237 5,603,798 8,702,237 5,603,595 Diluted net loss per share $ (0.28 ) $ (0.61 ) $ (0.90 ) $ (1.94 )	Year Ended April 30, 2015 2014 Basic loss per share computation Net loss attributable to common stockholders $ (13,139,820) $ (7,406,367) Weighted Average common shares – basic 5,985,346 5,571,993 Basic net loss per share $ (2.20) $ (1.33) Diluted loss per share computation Net loss attributable to common stockholders $ (13,139,820) $ (7,406,367) Less: Gain on derivative warrant liability 980,519 — Loss available to common stockholders $ (14,120,339) $ (7,406,367) Weighted Average common shares 5,985,346 5,571,993 Incremental shares from assumed exercise of warrants and stock options 439,065 — Adjusted weighted average share – diluted 6,424,410 5,571,993 Diluted net loss per share $ (2.20) $ (1.33)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	January 31, 2016 2015 Stock options 2,212,571 1,999,167 Warrants 2,109,840 260,556 Total common stock equivalents 4,322,411 2,259,723	Year Ended April 30, 2015 2014 Stock options 2,004,002 1,945,920 Warrants 2,109,840 273,056 Total common stock equivalents 4,113,842 2,218,975

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended	12 Months Ended
	Jan. 31, 2016	Apr. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment consisted of the following (table in thousands): January 31, April 30, 2016 2015 (unaudited) Furniture and fixtures $ 73 $ 70 Computer equipment and software 710 685 Laboratory equipment 641 493 Leasehold improvements 2 2 Total property and equipment 1,426 1,250 Less: Accumulated depreciation (912) (798) Property and equipment, net $ 514 $ 452
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	The following is a schedule by years of future minimum lease payments under this capital lease together with the present value of the net minimum lease payments as of January 31, 2016 (table in thousands): For the Years Ended April 30, Total 2016 (remaining) $ 6 2017 24 2018 25 2019 27 2020 16 Total minimum payments 98 Less: amount representing interest (10) Present value of minimum payments 88 Less: current portion (24) $ 64	For the Years Ended April 30, 2016 23 2017 24 2018 25 2019 26 2020 16 Total minimum lease payments $ 114 Less: current maturity (23) Long-term maturity 91

Share-Based Payments (Tables)

Share-Based Payments (Tables)	9 Months Ended	12 Months Ended
	Jan. 31, 2016	Apr. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Stock-based compensation expense was recognized as follows (table in thousands): Three Months Ended Nine Months Ended 2016 2015 2016 2015 General and administrative $ 488 $ 474 $ 1,600 $ 1,530 Sales and marketing 27 114 173 447 Research and development 49 65 262 267 TOS cost of sales 2 2 28 20 POS cost of sales 1 2 27 20 Total stock-based compensation expense $ 567 $ 657 $ 2,090 $ 2,284	Year Ended April 30, 2015 2014 General and administrative $ 2,204 $ 2,298 Sales and marketing 561 352 Research and development 352 36 TOS cost of sales 23 56 POS cost of sales 22 65 Total stock-based compensation expense $ 3,162 $ 2,807
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended Nine Months Ended 2016 2015 2016 2015 Expected term in years 2.5 – 6 — 2.5 – 6 3 – 6 Risk-free interest rates 0.995% – 1.75% — 0.995% – 1.77% 0.79% – 1.94% Volatility 82.72% – 91.98% — 82.72% – 92.32% 85.8% – 102.1% Dividend yield 0% — 0% 0%	Year Ended April 30, 2015 2014 Expected term in years 2.5 – 6.0 3.0 – 6.0 Risk-free interest rates 0.8% – 1.9% 0.7% – 2.4% Volatility 86% – 102% 84% – 102% Dividend yield 0% 0%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Non- Directors Total Weighted Weighted Aggregate Outstanding, May 1, 2015 57,917 1,946,085 2,004,002 $ 5.74 6.7 $ 4,166,000 Granted — 331,582 331,582 5.33 8.9 — Exercised — — — — Forfeited — (38,140 ) (38,140 ) 6.64 Expired (6,667 ) (78,206 ) (84,873 ) 6.91 Outstanding, January 31, 2016 51,250 2,161,321 2,212,571 5.61 6.4 $ 1,000 Vested and expected to vest as of January 31, 2016 51,250 2,161,321 2,212,571 5.61 6.4 $ 1,000 Exercisable as of January 31, 2016 34,271 1,644,223 1,678,494 5.76 5.8 $ 1,000	The Company’s stock options activity and related information as of and for the years ended April 30, 2015 and 2014 is as follows (dollars in thousands): Non- Employees Directors Total Weighted Weighted Aggregate Outstanding, May 1, 2014 63,750 1,882,170 1,945,920 $ 12.12 7.5 $ 985,000 Granted 6,667 1,756,714 1,763,380 7.92 Exercised — (313 ) (313 ) 5.88 Canceled — (1,656,073 ) (1,656,073 ) 12.48 Forfeited — (12,604 ) (12,604 ) 11.52 Expired (12,500 ) (23,809 ) (36,309 ) 11.88 Outstanding, April 30, 2015 57,917 1,946,085 2,004,002 5.74 6.7 $ 4,166,000 Vested and expected to vest as of April 30, 2015 57,917 1,946,085 2,004,002 6.7 $ 4,166,000 Vested as of April 30, 2015 40,625 1,385,298 1,425,923 5.88 5.9 $ 2,879,000 Non- Directors Total Weighted Weighted Aggregate Outstanding, May 1, 2013 63,750 1,093,767 1,157,517 $ 10.20 7.0 $ 89,000 Granted — 816,111 816,111 14.76 Exercised — (2,813 ) (2,813 ) 7.56 Canceled — — — — Forfeited — (6,042 ) (6,042 ) 9.84 Expired — (18,854 ) (18,854 ) 8.76 Outstanding, April 30, 2014 63,750 1,882,170 1,945,920 12.12 7.5 $ 985,000 Vested and expected to vest as of April 30, 2014 63,750 1,882,170 1,945,920 7.5 $ 985,000 Vested as of April 30, 2014 43,524 1,086,857 1,130,381 10.20 6.1 $ 927,000
Schedule Of Share Based Compensation Warrants Activity [Table Text Block]	Activity related to these warrants, which expire at various dates through January 2019, is summarized as follows: Number of Weighted Weighted Aggregate Outstanding, May 1, 2015 2,109,840 $ 5.54 4.6 $ 3,764,871 Granted — — — — Exercised — — — — Expired — — — — Outstanding, January 31, 2016 2,109,840 $ 5.54 3.9 $ —	Number of Weighted Weighted Aggregate Outstanding, May 1, 2014 273,056 $ 7.32 2.9 $ 984,333 Granted 1,849,285 5.64 4.9 3,108,271 Exercised — — — — Forfeited — — — — Expired (12,500 ) — — — Outstanding, April 30, 2015 2,109,840 $ 5.82 4.6 $ 3,247,604 Number of Weighted Weighted Aggregate Outstanding, May 1, 2013 273,056 $ 7.32 3.9 $ — Granted — — — — Exercised — — — — Forfeited — — — — Expired — — — — Outstanding, April 30, 2014 273,056 $ 7.32 2.9 $ 984,333

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Apr. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Future minimum lease payments due each fiscal year are as follows (in thousands): 2017 $ 192,013 2018 64,149 2019 — Total $ 256,162

Common Stock and Stock Purcha28

Common Stock and Stock Purchase Warrants (Tables)	12 Months Ended
	Apr. 30, 2015
Common Stock and Stock Purchase Warrant [Abstract]
Schedule of Share-based Payment Award Stock Warrants Valuation Assumptions [Table Text Block]	Assumptions used to calculate the fair value of these warrants were as follows: Year Ended April 30, 2015 2014 Expected term in years 1.1 – 4.9 1.9 – 3.7 Risk-free interest rates 0.5% – 1.76% 0.4% – 1.17% Volatility 73% – 107% 95% – 113% Dividend yield 0% 0%

Provision for Income Taxes (Tab

Provision for Income Taxes (Tables)	12 Months Ended
	Apr. 30, 2015
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year Ended April 30, 2015 Federal State Foreign Total Current $ — $ 3 $ 124 $ 127 Deferred (25,948 ) (1,771 ) 8 (27,711 ) Change in valuation allowance 25,948 1,771 (8 ) 27,711 Total $ — $ 3 $ 124 $ 127 Year Ended April 30, 2014 Federal State Foreign Total Current $ — $ 5 $ 12 $ 17 Deferred (2,015 ) (148 ) — (2,163 ) Change in valuation allowance 2,015 148 — 2,163 Total $ — $ 5 $ 12 $ 17
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	A reconciliation between the Company’s effective tax rate and the United States statutory tax rate for the years ended April 30, 2015 and 2014 is as follows: Year Ended April 30, 2015 2014 Federal income tax at statutory rate 34.0 % 34.0 % State income tax, net of federal benefit 2.6 2.1 Permanent differences 0.9 (5.6 ) Increase in uncertain tax position (0.8 ) — Other (6.9 ) (2.1 ) Change in valuation allowance (30.8 ) (27.2 ) Changes in tax rates — (1.4 )
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of April 30, 2015 2014 Accrued liabilities $ 21 $ 38 Depreciation and amortization — 9 State taxes 1 1 Stock-based compensation expense 4,803 4,511 Capitalized research and development costs 433 556 Foreign net operating loss carry-forward 235 244 Net operating loss carry-forward 9,719 5,608 Total deferred tax assets 15,212 10,968 Less: Valuation allowance (15,212 ) (10,968 ) Net deferred tax asset $ — $ —
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	The following table indicates the changes to the Company’s uncertain tax positions for the period and years ended April 30, 2015 and 2014 in thousands: Year Ended April 30, 2015 2014 Balance, beginning of the year $ — $ — Addition based on tax positions related to prior years 21 — Addition based on tax positions related to current year 79 — Balance, end of year $ 100 $ —

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended	12 Months Ended
	Jan. 31, 2016	Apr. 30, 2015
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	The following tables summarize, for the periods indicated, operating results by reportable segment (table in thousands): Three Months Ended January 31, 2016 Personalized Translational Unallocated Consolidated Net revenue $ 416 $ 2,136 $ — $ 2,552 Direct cost of services (479 ) (1,624 ) — (2,103 ) Sales and marketing costs (183 ) (569 ) — (752 ) Other operating expenses — (950 ) (553 ) (1,503 ) Stock-based compensation expense (1) — — (567 ) (567 ) Segment profit (loss) $ (246 ) $ (1,007 ) $ (1,120 ) $ (2,373 ) Three Months Ended January 31, 2015 Personalized Translational Unallocated Consolidated Net revenue $ 453 $ 1,376 $ — $ 1,829 Direct cost of services (672 ) (1,300 ) — (1,972 ) Sales and marketing costs (366 ) (613 ) — (979 ) Other operating expenses — (1,028 ) (612 ) (1,640 ) Stock-based compensation expense (1) — — (657 ) (657 ) Segment profit (loss) $ (585 ) $ (1,565 ) $ (1,269 ) $ (3,419 ) Nine Months Ended January 31, 2016 Personalized Translational Unallocated Consolidated Net revenue $ 1,387 $ 6,958 $ — $ 8,345 Direct cost of services (1,634 ) (4,654 ) — (6,288 ) Sales and marketing costs (716 ) (1,800 ) — (2,516 ) Other operating expenses — (2,755 ) (2,463 ) (5,218 ) Stock-based compensation expense (1) — — (2,090 ) (2,090 ) Segment profit (loss) $ (963 ) $ (2,251 ) $ (4,553 ) $ (7,767 ) Nine Months Ended January 31, 2015 Personalized Translational Unallocated Consolidated Net revenue $ 1,245 $ 4,377 $ — $ 5,622 Direct cost of services (2,171 ) (3,205 ) — (5,376 ) Sales and marketing costs (1,243 ) (1,650 ) — (2,893 ) Other operating expenses — (3,490 ) (2,413 ) (5,903 ) Stock-based compensation expense (1) — — (2,284 ) (2,284 ) Segment profit (loss) $ (2,169 ) $ (3,968 ) $ (4,697 ) $ (10,834 ) (1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.	Year Ended April 30, 2015 Personalized Translational Unallocated Consolidated Net revenue $ 1,663 $ 7,200 $ — $ 8,863 Direct cost of services (2,711 ) (4,877 ) — (7,588 ) Sales and marketing costs (1,514 ) (2,208 ) — (3,722 ) Other operating expenses — (4,493 ) (3,136 ) (7,729 ) Stock compensation expense (1) — — (3,162 ) (3,162 ) Segment profit (loss) $ (2,562 ) $ (4,378 ) $ (6,298 ) $ (13,238 ) Year Ended April 30, 2014 Personalized Translational Unallocated Consolidated Net revenue $ 2,264 $ 9,286 $ — $ 11,550 Direct cost of services (2,667 ) (3,496 ) — (6,163 ) Sales and marketing costs (1,723 ) (1,080 ) — (2,803 ) Other operating expenses — (2,209 ) (3,828 ) (6,037 ) Stock compensation expense (1) — — (2,807 ) (2,807 ) Segment loss $ (2,126 ) $ 2,501 $ (6,635 ) $ (6,260 ) (1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.

Organization, Use of Estimate31

Organization, Use of Estimates and Basis of Presentation (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015	Jan. 31, 2016	Jan. 31, 2015	Apr. 30, 2015	Apr. 30, 2014
Basic loss per share computation
Net loss attributable to common stockholders	$ (2,412,000)	$ (2,816,000)	$ (7,872,000)	$ (9,463,000)	$ (13,140,000)	$ (7,406,000)
Weighted Average common shares - basic (in shares)	8,702,237	5,574,447	8,702,237	5,574,244	5,985,346	5,571,993
Basic net loss per share (in dollars per share)	$ (0.28)	$ (0.51)	$ (0.90)	$ (1.70)	$ (2.20)	$ (1.33)
Diluted loss per share computation
Net loss attributable to common stockholders	$ (2,412,000)	$ (2,816,000)	$ (7,872,000)	$ (9,463,000)	$ (13,140,000)	$ (7,406,000)
Less: Gain on derivative warrant liability	0	620,687	0	1,401,314	980,519	0
Loss available to common stockholders	$ (2,412,381)	$ (3,437,152)	$ (7,872,115)	$ (10,863,595)	$ (14,120,339)	$ (7,406,367)
Weighted Average common shares (in shares)	8,702,237	5,574,447	8,702,237	5,574,244	5,985,346	5,571,993
Incremental shares from assumed exercise of warrants and stock options	0	29,351	0	29,351	439,065	0
Adjusted weighted average share - diluted (in shares)	8,702,237	5,603,798	8,702,237	5,603,595	6,424,410	5,571,993
Diluted net loss per share (in dollars per shares)	$ (0.28)	$ (0.61)	$ (0.90)	$ (1.94)	$ (2.20)	$ (1.33)

Organization, Use of Estimate32

Organization, Use of Estimates and Basis of Presentation (Details 1) - shares	9 Months Ended		12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015	Apr. 30, 2015	Apr. 30, 2014
Total common stock equivalents	4,322,411	2,259,723	4,113,842	2,218,975
Stock options [Member]
Total common stock equivalents	2,212,571	1,999,167
Warrants [Member]
Total common stock equivalents	2,109,840	260,556

Organization, Use of Estimate33

Organization, Use of Estimates and Basis of Presentation (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015	Jan. 31, 2016	Jan. 31, 2015	Apr. 30, 2015	Apr. 30, 2014	Apr. 30, 2013
Working Capital Deficit	$ 1,200		$ 1,200
Cash Equivalents, at Carrying Value	3,300		3,300
Unrecognized Tax Benefits	165		165		$ 100	$ 0	$ 0
Income Tax Expense (Benefit)	$ 31	$ 12	$ 76	$ 27	$ 127	$ 17

Summary of Significant Accoun34

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2015	Apr. 30, 2014
Balance beginning of year	$ (2,011)
Modification Charge	(586)	$ 0
Balance end of year	0	(2,011)
Fair Value, Inputs, Level 3 [Member]
Balance beginning of year	(2,011)	(1,046)
Transfers to (from) Level 3	0	0
Change in fair value included in earnings	981	(965)
Modification Charge	(586)
Reclassification to equity	1,616	0
Balance end of year	$ 0	$ (2,011)

Summary of Significant Accoun35

Summary of Significant Accounting Policies (Details 1) - USD ($) $ in Thousands	Jan. 31, 2016	Apr. 30, 2015	Apr. 30, 2014
Furniture and fixtures	$ 73	$ 70	$ 69
Computer equipment and software	710	685	655
Laboratory equipment	641	493	296
Leasehold improvements	2	2	2
Total property and equipment	1,426	1,250	1,022
Less: Accumulated depreciation and amortization	(912)	(798)	(588)
Property and equipment, net	$ 514	$ 452	$ 434

Summary of Significant Accoun36

Summary of Significant Accounting Policies (Details 2) - USD ($) $ in Thousands	Jan. 31, 2016	Apr. 30, 2015
2,016	$ 6	$ 23
2,017	24	24
2,018	25	25
2,019	27	26
2,020	16	16
Total minimum payments	98	114
Less: current portion	(24)	(23)
Long-term maturity	$ 64	$ 91

Summary of Significant Accoun37

Summary of Significant Accounting Policies (Details 3) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015	Jan. 31, 2016	Jan. 31, 2015	Apr. 30, 2015	Apr. 30, 2014
Basic loss per share computation
Net loss attributable to common stockholders	$ (2,412,000)	$ (2,816,000)	$ (7,872,000)	$ (9,463,000)	$ (13,140,000)	$ (7,406,000)
Weighted Average common shares - basic (in shares)	8,702,237	5,574,447	8,702,237	5,574,244	5,985,346	5,571,993
Basic net loss per share (in dollars per share)	$ (0.28)	$ (0.51)	$ (0.90)	$ (1.70)	$ (2.20)	$ (1.33)
Diluted loss per share computation
Net loss attributable to common stockholders	$ (2,412,000)	$ (2,816,000)	$ (7,872,000)	$ (9,463,000)	$ (13,140,000)	$ (7,406,000)
Less: Gain on derivative warrant liability	0	620,687	0	1,401,314	980,519	0
Loss available to common stockholders	$ (2,412,381)	$ (3,437,152)	$ (7,872,115)	$ (10,863,595)	$ (14,120,339)	$ (7,406,367)
Weighted Average common shares (in shares)	8,702,237	5,574,447	8,702,237	5,574,244	5,985,346	5,571,993
Incremental shares from assumed exercise of warrants and stock options (in shares)	0	29,351	0	29,351	439,065	0
Adjusted weighted average share - diluted (in shares)	8,702,237	5,603,798	8,702,237	5,603,595	6,424,410	5,571,993
Diluted net loss per share (in dollars per shares)	$ (0.28)	$ (0.61)	$ (0.90)	$ (1.94)	$ (2.20)	$ (1.33)

Summary of Significant Accoun38

Summary of Significant Accounting Policies (Details 4) - shares	9 Months Ended		12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015	Apr. 30, 2015	Apr. 30, 2014
Total common stock equivalents	4,322,411	2,259,723	4,113,842	2,218,975
Employee Stock Option [Member]
Total common stock equivalents			2,004,002	1,945,920
Warrant [Member]
Total common stock equivalents			2,109,840	273,056

Summary of Significant Accoun39

Summary of Significant Accounting Policies (Details Textual) - USD ($)	9 Months Ended		12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015	Apr. 30, 2015	Apr. 30, 2014	Mar. 11, 2015	Nov. 30, 2014	Apr. 30, 2013
Estimated Fair Value Of Warrants				$ 2,000,000	$ 1,600,000
Allowance for Doubtful Accounts Receivable			$ 2,000	2,000
Unbilled Receivables, Current			636,000	884,000
Restricted Cash and Cash Equivalents, Noncurrent	$ 150,000		163,000	165,000
Depreciation, Depletion and Amortization, Total			214,000	213,000
Deferred Revenue			$ 258,000
Capital Leases, Future Minimum Payments, Executory Costs						$ 149,000
Capital Leases of Lessee, Contingent Rentals, Basis Spread on Variable Rate			5.00%
Capital Leases, Income Statement, Amortization Expense			$ 12,405
Unrecognized Tax Benefits	165,000		100,000	0			$ 0
Capital Leases Monthly Payments						$ 3,000
Capital Lease Obligations Incurred	$ 0	$ 124,000	$ 124,000	$ 0

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	Jan. 31, 2016	Apr. 30, 2015	Apr. 30, 2014
Furniture and fixtures	$ 73	$ 70	$ 69
Computer equipment and software	710	685	655
Laboratory equipment	641	493	296
Leasehold improvements	2	2	2
Total property and equipment	1,426	1,250	1,022
Less: Accumulated depreciation	(912)	(798)	(588)
Property and equipment, net	$ 514	$ 452	$ 434

Property and Equipment (Detai41

Property and Equipment (Details 1) - USD ($) $ in Thousands	Jan. 31, 2016	Apr. 30, 2015
2016 (remaining)	$ 6	$ 23
2,017	24	24
2,018	25	25
2,019	27	26
2,020	16	16
Total minimum payments	98	114
Less: amount representing interest	(10)
Present value of minimum payments	88
Less: current portion	(24)	(23)
Capital Leases Future Minimum Payments Due Total	$ 64	$ 91

Property and Equipment (Detai42

Property and Equipment (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Nov. 30, 2014	Jan. 31, 2016	Jan. 31, 2015	Jan. 31, 2016	Jan. 31, 2015	Apr. 30, 2015
Depreciation		$ 31,000	$ 52,000	$ 95,000	$ 166,000
Capital Leased Assets, Gross		124,000		$ 124,000		$ 124,000
Monthly Capital Lease Payment	$ 3,000
Capital Lease Minimum Lease Payment Percentage				5.00%
Equipment Leased to Other Party [Member]
Capital Leases, Balance Sheet, Assets by Major Class, Net, Total	$ 149,000
Assets Held under Capital Leases [Member]
Depreciation		$ 6,000	$ 6,000	$ 19,000	$ 12,000

Share-Based Payments (Details)

Share-Based Payments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015	Jan. 31, 2016	Jan. 31, 2015	Apr. 30, 2015	Apr. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 567	$ 657	$ 2,090	$ 2,284	$ 3,162	$ 2,807
General and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	488	474	1,600	1,530	2,204	2,298
Sales and marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	27	114	173	447	561	352
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	49	65	262	267	352	36
TOS cost of sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	2	2	28	20	23	56
POS cost of sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1	$ 2	$ 27	$ 20	$ 22	$ 65

Share-Based Payments (Details 1

Share-Based Payments (Details 1)	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015	Jan. 31, 2016	Jan. 31, 2015	Apr. 30, 2015	Apr. 30, 2014
Expected term in years		0 years
Risk-free interest rates Minimum	0.995%		0.995%	0.79%	0.80%	0.70%
Risk-free interest rates Maximum	1.75%		1.77%	1.94%	1.90%	2.40%
Risk-free interest rates		0.00%
Volatility Minimum	82.72%		82.72%	85.80%	86.00%	84.00%
Volatility Maximum	91.98%		92.32%	102.10%	102.00%	102.00%
Volatility		0.00%
Dividend yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Minimum [Member]
Expected term in years	2 years 6 months		2 years 6 months	3 years	2 years 6 months	3 years
Maximum [Member]
Expected term in years	6 years		6 years	6 years	6 years	6 years

Share-Based Payments (Details 2

Share-Based Payments (Details 2) - USD ($)	9 Months Ended	12 Months Ended
	Jan. 31, 2016	Apr. 30, 2015	Apr. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Outstanding, Beginning Balance	2,004,002	1,945,920	1,157,517
Shares, Granted	331,582	1,763,380	816,111
Shares, Exercised	0	(313)	(2,813)
Shares, Canceled		(1,656,073)	0
Shares, Forfeited	(38,140)	(12,604)	(6,042)
Shares, Expired	(84,873)	(36,309)	(18,854)
Shares, Outstanding, Ending Balance	2,212,571	2,004,002	1,945,920
Shares, Vested and expected to vest	2,212,571	2,004,002	1,945,920
Shares, Exercisable	1,678,494	1,425,923	1,130,381
Weighted Average Exercise Price, Outstanding, Beginning Balance	$ 5.74	$ 12.12	$ 10.20
Weighted Average Exercise Price, Granted	5.33	7.92	14.76
Weighted Average Exercise Price, Exercised	0	5.88	7.56
Weighted Average Exercise Price, Canceled		12.48	0
Weighted Average Exercise Price, Forfeited	6.64	11.52	9.84
Weighted Average Exercise Price, Expired	6.91	11.88	8.76
Weighted Average Exercise Price, Outstanding, Ending Balance	5.61	5.74	12.12
Weighted Average Exercise Price, Vested and expected to vest	5.61
Weighted Average Exercise Price, Exercisable	$ 5.76	$ 5.88	$ 10.20
Weighted Average Remaining Contractual Term, Outstanding, Beginning Balance (in years)	6 years 8 months 12 days	7 years 6 months	7 years
Weighted Average Remaining Contractual Life (Years), Granted	8 years 10 months 24 days
Weighted Average Remaining Contractual Term, Outstanding, Ending Balance (in years)	6 years 4 months 24 days	6 years 8 months 12 days	7 years 6 months
Weighted Average Remaining Contractual Life (Years), Vested and expected to vest	6 years 4 months 24 days	6 years 8 months 12 days	7 years 6 months
Weighted Average Remaining Contractual Life (Years), Exercisable	5 years 9 months 18 days	5 years 10 months 24 days	6 years 1 month 6 days
Aggregate Intrinsic Value, Outstanding, Beginning Balance	$ 4,166,000	$ 985,000	$ 89,000
Aggregate Intrinsic Value, Granted	0
Aggregate Intrinsic Value, Outstanding, Ending Balance	1,000	4,166,000	985,000
Aggregate Intrinsic Value, Vested and expected to vest	1,000	4,166,000	985,000
Aggregate Intrinsic Value, Exercisable	$ 1,000	$ 2,879,000	$ 927,000
Non-Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Outstanding, Beginning Balance	57,917	63,750	63,750
Shares, Granted	0	6,667	0
Shares, Exercised	0	0	0
Shares, Canceled		0	0
Shares, Forfeited	0	0	0
Shares, Expired	(6,667)	(12,500)	0
Shares, Outstanding, Ending Balance	51,250	57,917	63,750
Shares, Vested and expected to vest	51,250	57,917	63,750
Shares, Exercisable	34,271	40,625	43,524
Directors and Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Outstanding, Beginning Balance	1,946,085	1,882,170	1,093,767
Shares, Granted	331,582	1,756,714	816,111
Shares, Exercised	0	(313)	(2,813)
Shares, Canceled		(1,656,073)	0
Shares, Forfeited	(38,140)	(12,604)	(6,042)
Shares, Expired	(78,206)	(23,809)	(18,854)
Shares, Outstanding, Ending Balance	2,161,321	1,946,085	1,882,170
Shares, Vested and expected to vest	2,161,321	1,946,085	1,882,170
Shares, Exercisable	1,644,223	1,385,298	1,086,857

Share-Based Payments (Details 3

Share-Based Payments (Details 3) - Warrant [Member] - USD ($)	9 Months Ended	12 Months Ended
	Jan. 31, 2016	Apr. 30, 2015	Apr. 30, 2014	Apr. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning Balance	2,109,840	273,056	273,056
Number of Shares, Granted	0	1,849,285	0
Number of Shares, Exercised	0	0	0
Number of Shares, Forfeited		0	0
Number of Shares, Expired	0	(12,500)	0
Number of Shares, Ending Balance	2,109,840	2,109,840	273,056	273,056
Weighted Average Exercise Price, Beginning Balance	$ 5.54	$ 7.32	$ 7.32
Weighted Average Exercise Price, Granted	0	5.64	0
Weighted Average Exercise Price, Exercised	0	0	0
Weighted Average Exercise Price, Forfeited		0	0
Weighted Average Exercise Price, Expired	0	0	0
Weighted Average Exercise Price, Ending Balance	$ 5.54	$ 5.54	$ 7.32	$ 7.32
Weighted Average Remaining Contractual Life (Years), Balance	3 years 10 months 24 days	4 years 7 months 6 days	2 years 10 months 24 days	3 years 10 months 24 days
Weighted Average Remaining Contractual Life (Years), Granted		4 years 10 months 24 days
Aggregate Intrinsic Value, Beginning Balance	$ 3,764,871	$ 984,333	$ 0
Aggregate Intrinsic Value, Granted	0	3,108,271
Aggregate Intrinsic Value, Ending Balance	$ 0	$ 3,764,871	$ 984,333	$ 0

Share-Based Payments (Details T

Share-Based Payments (Details Textual) - USD ($)	Dec. 12, 2013	Feb. 18, 2011	Jan. 31, 2016	Jan. 31, 2015	Jan. 31, 2016	Jan. 31, 2015	Apr. 30, 2015	Apr. 30, 2014
Stock-based compensation expense			$ 567,000	$ 657,000	$ 2,090,000	$ 2,284,000	$ 3,162,000	$ 2,807,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 3.12		$ 3.60	$ 8.04	$ 7.32	$ 11.52
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					331,582		1,763,380	816,111
Share-based Compensation Arrangement by Share-based Payment Award, Vesting Period, Fair Value							$ 0	$ 15,000
Stock options award Shares to purchase common Stock	16,667
Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding			2,109,840		2,109,840		2,109,840
Share Based Compensation Arrangement By Share Based Payment Award Shares Exchanged In Period							1,656,073
Share Based Compensation Arrangement By Share Based Payment Award Options For Exchanges In Period Weighted Average Exercise Price							$ 4.92
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period							1,468,161
Stock or Unit Option Plan Expense							$ 213,951
Additional Stock Option Plan Expense							386,578
General and Administrative Expense [Member]
Stock-based compensation expense			$ 488,000	$ 474,000	$ 1,600,000	$ 1,530,000	2,204,000	$ 2,298,000
Stock or Unit Option Plan Expense							$ 213,952
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award Options For Exchanges In Period Weighted Average Exercise Price							$ 5.64
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award Options For Exchanges In Period Weighted Average Exercise Price							$ 15.96
Equity Incentive Plan 2010 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total		30,000,000
Director Compensation Plan [Member]
Stock options award Shares to purchase common Stock	8,333
Stock Options Award Shares To Purchase Unregistered Common Stock	1,667
Share Based Compensation Arrangement by Share Based Payment Award Options Vested Percentage	25.00%
Chief Executive Officer and President [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					224,663		224,663
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total					224,663		224,663
Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							96,283
President [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							90,358
March 2015 Private Placement [Member]
Warrants Issued During Period for Common Stock					1,849,285		1,849,285

Related Party Transactions (Det

Related Party Transactions (Details Textual) - USD ($)	1 Months Ended		9 Months Ended		12 Months Ended
	Jan. 28, 2013	Mar. 24, 2011	Jan. 31, 2016	Jan. 31, 2015	Apr. 30, 2015	Apr. 30, 2014
Common Stock Purchase Price	$ 6	$ 9
Private Placement [Member]
Warrants Issued During Period For Common Stock					248,460
Warrants Exercise Price Per Share					$ 4.80
Stock Issued During Period, Shares, Issued for Services					451,754
Common Stock Purchase Price					$ 5.76
Board of Directors Chairman [Member]
Consulting Service Fees			$ 54,000	$ 75,000	$ 62,500	$ 150,000
Substantial Stockholders [Member]
Consulting Service Fees			$ 8,800	$ 0
Board [Member]
Consulting Service Fees					$ 3,700	$ 15,800

Commitments and Contingencies49

Commitments and Contingencies (Details) $ in Thousands	Apr. 30, 2015USD ($)
Operating Leased Assets [Line Items]
2,017	$ 192,013
2,018	64,149
2,019	0
Total	$ 256,162

Commitments and Contingencies50

Commitments and Contingencies (Details Textual) - USD ($)	9 Months Ended		12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015	Apr. 30, 2015	Apr. 30, 2014
Corporate Headquarters [Member]
Commitments and Contingencies [Line Items]
Lease Expiration Date	Nov. 30, 2016		Nov. 30, 2016
Operating Leases, Rent Expense	$ 64,000	$ 64,000	$ 85,000	$ 75,000
Laboratories and Office Space [Member]
Commitments and Contingencies [Line Items]
Lease Expiration Date	Jun. 30, 2016		Jun. 30, 2016
Operating Leases, Rent Expense	$ 65,000	65,000	$ 86,000	85,000
Israel Office Headquarters [Member]
Commitments and Contingencies [Line Items]
Operating Leases, Rent Expense			$ 0	6,000
Singapore Office Headquarters in Singapore [Member]
Commitments and Contingencies [Line Items]
Lease Expiration Date	Jan. 31, 2015		Jan. 31, 2015
Operating Leases, Rent Expense	$ 0	4,000	$ 4,000	5,000
New York Laboratory [Member]
Commitments and Contingencies [Line Items]
Lease Expiration Date	Sep. 30, 2016		Sep. 30, 2015
Operating Leases, Rent Expense	$ 87,000	$ 35,000	$ 47,000	$ 4,000

Teva Agreement (Details Textual

Teva Agreement (Details Textual) - USD ($)	9 Months Ended		12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015	Apr. 30, 2015	Apr. 30, 2014
Deferred Revenue, Revenue Recognized	$ 48,000	$ 574,000	$ 724,000	$ 194,000

Significant Customers (Details

Significant Customers (Details Textual) - USD ($)	12 Months Ended
	Apr. 30, 2015	Apr. 30, 2014
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	10.00%	10.00%
Accounts Receivable [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	10.00%	10.00%
Customer One [Member]
Revenue, Major Customer [Line Items]
Revenues	$ 900,000	$ 1,600,000
Accounts Receivable, Gross	$ 153,446	$ 398,053
Customer One [Member] | Accounts Receivable [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	14.50%	30.40%
Customer Two [Member]
Revenue, Major Customer [Line Items]
Revenues	$ 900,000	$ 1,500,000
Accounts Receivable, Gross	$ 119,540	$ 171,962
Customer Two [Member] | Accounts Receivable [Member]
Revenue, Major Customer [Line Items]
Concentration Risk, Percentage	11.30%	13.20%
Customer Three [Member]
Revenue, Major Customer [Line Items]
Revenues	$ 800,000	$ 1,500,000

Common Stock and Stock Purcha53

Common Stock and Stock Purchase Warrants (Details)	12 Months Ended
	Apr. 30, 2015	Apr. 30, 2014
Dividend yield	0.00%	0.00%
Minimum [Member]
Expected term in years	1 year 1 month 6 days	1 year 10 months 24 days
Risk-free interest rates	0.50%	0.40%
Volatility	73.00%	95.00%
Maximum [Member]
Expected term in years	4 years 10 months 24 days	3 years 8 months 12 days
Risk-free interest rates	1.76%	1.17%
Volatility	107.00%	113.00%

Common Stock and Stock Purcha54

Common Stock and Stock Purchase Warrants (Details Textual) - USD ($)	Mar. 11, 2015	Dec. 31, 2015	Feb. 28, 2015	Jan. 28, 2013	Mar. 24, 2011	Apr. 30, 2015	Apr. 30, 2014	Jan. 31, 2016	Dec. 01, 2014
Stock Issued During Period, Shares, Acquisitions				1,550,000	1,044,444
Common Stock Purchase Price				$ 6	$ 9
Stock Issued During Period, Value, Share-based Compensation, Gross				$ 9,300,000	$ 9,400,000
Issuance of Additional Common Shares to Investors						1,468,161
Proceeds from Issuance of Common Stock and Warrants				$ 9,100,000
Debt Conversion, Original Debt, Amount		$ 1,000,000
Repurchase Of Stock In Put Option						$ 4.80
Common Stock, Shares Authorized						200,000,000	125,000,000	200,000,000
Warrant Modification Charge						$ 586,000	$ 0
Securities Purchase Agreement 2011 [Member]
Warrants Exercise Price Per Share					$ 4.80
Stock Issued During Period, Shares, New Issues					188,704
Additional Warrants Issued To Investors					131,945
Warrant Modification Charge					$ 413,521
Securities Purchase Agreement 2013 [Member]
Warrants Exercise Price Per Share				$ 4.80
Additional Warrants Issued To Investors				100,750
Warrant Modification Charge				$ 172,344
Securities Purchase Agreement 2015 [Member]
Unit Description	$0.001 per share (the Common Stock) and a warrant to buy 0.55 shares of Common Stock at$5.76 per share (the Warrants), at a purchase price of $4.80 per unit, for an aggregate of $14,000,000.
Debt Instrument, Increase, Accrued Interest	$ 60,000
Debt Conversion Converted Instrument Discount Rate	5.00%
Convertible Promissory Notes [Member]
Short-term Debt, Percentage Bearing Fixed Interest Rate									12.00%
Short-term Debt, Terms		90 days
Debt Instrument, Maturity Date			Apr. 1, 2015
Term Of Warrants		5 years
Convertible Debt [Member]
Debt Instrument, Increase, Accrued Interest	$ 60,000
Debt Conversion Converted Instrument Discount Rate	5.00%
January 2013 Private Placement [Member]
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures				$ 500,000
Warrants Issued During Period for Common Stock						155,000
Warrants Exercise Price Per Share						$ 7.92
Percentage of Common Stock Purchased						25.00%
Issuance of Additional Common Shares to Investors						88,722
Net Shares Reclassified to Mandatorily Redeemable Capital Stock, Value						$ 8,800,000
Proceeds from Issuance of Common Stock and Warrants						9,300,000
Proceeds from Issuance of Warrants						400,000
Incremental Compensation Cost						$ 200,000
April 2011 Private Placement [Member]
Common Stock Purchase Price						$ 9
Warrants Issued During Period for Common Stock						105,556
Warrants Exercise Price Per Share						$ 10.80
Net Shares Reclassified to Mandatorily Redeemable Capital Stock, Value						$ 25
Proceeds from Issuance of Warrants						900,000
Incremental Compensation Cost						$ 300,000
April 2011 Private Placement [Member] | Minimum [Member]
Warrants Exercise Price Per Share						$ 6
April 2011 Private Placement [Member] | Maximum [Member]
Warrants Exercise Price Per Share						$ 10.80
March 2015 Private Placement [Member]
Net Shares Reclassified to Mandatorily Redeemable Capital Stock, Value						$ 8,000,000
Proceeds from Issuance of Common Stock and Warrants						14,000,000
Proceeds from Issuance of Warrants						100,000
Incremental Compensation Cost						880,000
Warrants and Rights Outstanding						$ 1,600,000

Provision for Income Taxes (Det

Provision for Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 31, 2016	Jan. 31, 2015	Jan. 31, 2016	Jan. 31, 2015	Apr. 30, 2015	Apr. 30, 2014
Provision for Income Taxes, Current, Federal					$ 0	$ 0
Provision for Income Taxes, Current, State					3	5
Provision for Income Taxes, Current, Foriegn					124	12
Provision for Income Taxes, Current, Total					127	17
Provision for Income Taxes, Deferred, Federal					(25,948)	(2,015)
Provision for Income Taxes, Deferred, State					(1,771)	(148)
Provision for Income Taxes, Deferred, Foreign					8	0
Provision for Income Taxes, Deferred, Total					(27,711)	(2,163)
Provision for Income Taxes, Change in valuation allowance, Federal					25,948	2,015
Provision for Income Taxes, Change in valuation allowance, State					1,771	148
Provision for Income Taxes, Change in valuation allowance, Foreign					(8)	0
Provision for Income Taxes, Change in valuation allowance, Total					27,711	2,163
Provision for Income Taxes, Total, Federal					0	0
Provision for Income Taxes, Total, State					3	5
Provision for Income Taxes, Total, Foreign					124	12
Provision for Income Taxes, Total	$ 31	$ 12	$ 76	$ 27	$ 127	$ 17

Provision for Income Taxes (D56

Provision for Income Taxes (Details 1)	12 Months Ended
	Apr. 30, 2015	Apr. 30, 2014
Federal income tax at statutory rate	34.00%	34.00%
State income tax, net of federal benefit	2.60%	2.10%
Permanent differences	0.90%	(5.60%)
Increase in uncertain tax position	(0.80%)	0.00%
Other	(6.90%)	(2.10%)
Change in valuation allowance	(30.80%)	(27.20%)
Changes in tax rates	0.00%	(1.40%)
Income tax expense	(1.10%)	(0.20%)

Provision for Income Taxes (D57

Provision for Income Taxes (Details 2) - USD ($) $ in Thousands	Apr. 30, 2015	Apr. 30, 2014
Accrued liabilities	$ 21	$ 38
Depreciation and amortization	0	9
State taxes	1	1
Stock-based compensation expense	4,803	4,511
Capitalized research and development costs	433	556
Foreign net operating loss carry-forward	235	244
Net operating loss carry-forward	9,719	5,608
Total deferred tax assets	15,212	10,968
Less: Valuation allowance	(15,212)	(10,968)
Net deferred tax asset	$ 0	$ 0

Provision for Income Taxes (D58

Provision for Income Taxes (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2015	Apr. 30, 2014
Balance, beginning of the year	$ 0	$ 0
Addition based on tax positions related to prior years	21	0
Addition based on tax positions related to current year	79	0
Balance, end of year	$ 100	$ 0

Provision for Income Taxes (D59

Provision for Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Apr. 30, 2015	Apr. 30, 2014
Deferred Tax Assets, Valuation Allowance	$ 15,212	$ 10,968
Liabilities, Other than Long-term Debt, Noncurrent	1,000	1,000
Domestic Tax Authority [Member]
Operating Loss Carryforwards	$ 26,000	$ 15,000
Operating Loss Carry forwards Expiration Year	2,022
Foreign Tax Authority [Member]
Operating Loss Carryforwards	$ 100,000,000
State and Local Jurisdiction [Member]
Operating Loss Carry forwards Expiration Year	2,017

Segment Information (Details)

Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended				9 Months Ended				12 Months Ended
	Jan. 31, 2016		Jan. 31, 2015		Jan. 31, 2016		Jan. 31, 2015		Apr. 30, 2015		Apr. 30, 2014
Net revenue	$ 2,552		$ 1,829		$ 8,345		$ 5,622		$ 8,863		$ 11,550
Sales and marketing costs	(779)		(1,094)		(2,688)		(3,340)		(4,283)		(3,155)
Stock-based compensation expense	567		657		2,090		2,284		3,162		2,807
Personalized Oncology Solutions [Member]
Net revenue	416		453		1,387		1,245		1,663		2,264
Direct cost of services	(479)		(672)		(1,634)		(2,171)		(2,711)		(2,667)
Sales and marketing costs	(183)		(366)		(716)		(1,243)		(1,514)		(1,723)
Other operating expenses	0		0		0		0		0		0
Stock-based compensation expense	0	[1]	0	[1]	0	[1]	0	[1]	0	[2]	0	[2]
Segment profit (loss)	(246)		(585)		(963)		(2,169)		(2,562)		(2,126)
Translational Oncology Solutions [Member]
Net revenue	2,136		1,376		6,958		4,377		7,200		9,286
Direct cost of services	(1,624)		(1,300)		(4,654)		(3,205)		(4,877)		(3,496)
Sales and marketing costs	(569)		(613)		(1,800)		(1,650)		(2,208)		(1,080)
Other operating expenses	(950)		(1,028)		(2,755)		(3,490)		(4,493)		(2,209)
Stock-based compensation expense	0	[1]	0	[1]	0	[1]	0	[1]	0	[2]	0	[2]
Segment profit (loss)	(1,007)		(1,565)		(2,251)		(3,968)		(4,378)		2,501
Unallocated Corporate Overhead [Member]
Net revenue	0		0		0		0		0		0
Direct cost of services	0		0		0		0		0		0
Sales and marketing costs	0		0		0		0		0		0
Other operating expenses	(553)		(612)		(2,463)		(2,413)		(3,136)		(3,828)
Stock-based compensation expense	(567)	[1]	(657)	[1]	(2,090)	[1]	(2,284)	[1]	(3,162)	[2]	(2,807)	[2]
Segment profit (loss)	(1,120)		(1,269)		(4,553)		(4,697)		(6,298)		(6,635)
Consolidated [Member]
Net revenue	2,552		1,829		8,345		5,622		8,863		11,550
Direct cost of services	(2,103)		(1,972)		(6,288)		(5,376)		(7,588)		(6,163)
Sales and marketing costs	(752)		(979)		(2,516)		(2,893)		(3,722)		(2,803)
Other operating expenses	(1,503)		(1,640)		(5,218)		(5,903)		(7,729)		(6,037)
Stock-based compensation expense	(567)	[1]	(657)	[1]	(2,090)	[1]	(2,284)	[1]	(3,162)	[2]	(2,807)	[2]
Segment profit (loss)	$ (2,373)		$ (3,419)		$ (7,767)		$ (10,834)		$ (13,238)		$ (6,260)
[1]	Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.
[2]	Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.